{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":3896,"total_is_capped":false,"direct_labels_cover":11,"predictions_cover":3896,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"c73cb4f6df46","filters":{"topic":"Diabetes Treatment and Management"}},"results":[{"id":"W2146264128","doi":"10.1056/nejmoa1504720","title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12000,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Empagliflozin; Medicine; Hazard ratio; Myocardial infarction; Internal medicine; Placebo; Confidence interval; Relative risk; Diabetes mellitus; Stroke (engine); Angina; Type 2 diabetes; Cardiology; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.03667286996223124,"gpt":0.2896293482684484,"spread":0.2529564783062172,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001361217,0.0001271733,0.000715279,0.0002004902,0.000008393732,0.000006139442,0.00005126102,0.000038621,0.00003948493],"category_scores_gemma":[0.0004266667,0.00007527038,0.00008114312,0.0001668377,0.00005852595,0.00007830213,0.00002494927,0.0001594309,0.000003515325],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005590723,"about_ca_system_score_gemma":0.00008935067,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009606587,"about_ca_topic_score_gemma":0.00003169207,"domain_scores_codex":[0.9988003,0.00005835696,0.0003584695,0.0001065406,0.0005067202,0.0001696317],"domain_scores_gemma":[0.9991512,0.00005332831,0.00009333454,0.0001904831,0.0001351986,0.0003764051],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001787485,0.00006794824,0.918018,0.00003954982,0.0008957813,0.000502502,0.0004364275,0.00001265454,0.00001684682,0.00003076572,0.003520293,0.07628046],"study_design_scores_gemma":[0.05833382,0.001807743,0.8552662,0.0002943588,0.001361596,0.00006198569,0.0001794313,0.00002120808,0.00003307484,0.000682053,0.08187098,0.0000876256],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9711436,0.02378549,0.00001448746,0.002634809,0.000555138,0.0001368483,3.861072e-7,0.000007956599,0.001721262],"genre_scores_gemma":[0.9970699,0.0008811075,0.0002459254,0.0005255445,0.0009053759,0.000001249522,0.000003770881,0.00001053301,0.0003566234],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07835069,"threshold_uncertainty_score":0.3069437,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1526927233","doi":"10.1056/nejmoa0802987","title":"Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes","year":2008,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7418,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"National Health and Medical Research Council; Medical Research Council; GW Pharmaceuticals; Gilead Sciences; Novo Nordisk; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Servier; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Hazard ratio; Glycated hemoglobin; Internal medicine; Type 2 diabetes; Retinopathy; Nephropathy; Diabetes mellitus; Diabetic retinopathy; Albuminuria; Incidence (geometry); Stroke (engine); Confidence interval; Endocrinology; Renal function","retraction":null,"screen_n_in":null,"score":{"opus":0.006932252723265506,"gpt":0.2100692941222603,"spread":0.2031370413989948,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002137836,0.0001387542,0.0006128887,0.0002153193,0.00002172288,0.000003091347,0.00004369381,0.00003022237,0.00003605599],"category_scores_gemma":[0.0003156579,0.00007197069,0.00003688799,0.0001202205,0.00009080408,0.00007241795,0.00001182951,0.0001540096,0.000001597038],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000218093,"about_ca_system_score_gemma":0.00004299034,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001712601,"about_ca_topic_score_gemma":0.000006999806,"domain_scores_codex":[0.9990453,0.00003292915,0.0002967105,0.00009957184,0.0003573026,0.0001682376],"domain_scores_gemma":[0.9991133,0.0001068737,0.000147999,0.0001090602,0.0003247737,0.0001980584],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005291179,0.0002302941,0.9854238,0.00002195335,0.0007840167,0.0002281058,0.000442978,0.000002418411,0.0000778221,0.000009196016,0.0008098155,0.01144047],"study_design_scores_gemma":[0.15432,0.006494056,0.8352917,0.0002972063,0.0008729087,0.00002446698,0.00006614866,0.000005571175,0.00004658077,0.00003078963,0.002487291,0.00006325437],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949793,0.002115577,0.00001000187,0.002304735,0.0001622985,0.0002343528,6.03144e-7,0.00000632454,0.0001868594],"genre_scores_gemma":[0.9973421,0.0006016428,0.0001885157,0.001396152,0.0002772215,9.983115e-7,0.000005643018,0.00001204485,0.0001756503],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1537909,"threshold_uncertainty_score":0.293488,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2425644022","doi":"10.1056/nejmoa1603827","title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7350,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"National Center for Advancing Translational Sciences; Relypsa; National Institutes of Health; ResMed; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Orexigen Therapeutics; Massachusetts Medical Society; Novo Nordisk; Intarcia Therapeutics; Sanofi; Esperion Therapeutics; GlaxoSmithKline; Amgen; Pfizer; Celgene","keywords":"Liraglutide; Type 2 diabetes; Medicine; Internal medicine; Diabetes mellitus; Cardiology; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.01427990771717185,"gpt":0.2462845114180889,"spread":0.232004603700917,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006895917,0.0001099473,0.0006025514,0.0002244424,0.00001094258,0.000003491054,0.00004875091,0.00003048071,0.0001103861],"category_scores_gemma":[0.0004070194,0.00004917575,0.00008082971,0.0001043231,0.00005987625,0.00007303841,0.0000201628,0.00008361498,0.000004969131],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003307353,"about_ca_system_score_gemma":0.000036876,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001921694,"about_ca_topic_score_gemma":0.000007994039,"domain_scores_codex":[0.9990858,0.00003804049,0.0002968724,0.0000975857,0.0003162799,0.0001654652],"domain_scores_gemma":[0.9993594,0.0001552572,0.00007796252,0.0001528041,0.00006742621,0.0001871889],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001215981,0.00004329258,0.5047436,0.0000251558,0.0006776187,0.0002132488,0.0001284607,9.502967e-7,0.0007582256,0.00007682592,0.002927558,0.4902835],"study_design_scores_gemma":[0.1121751,0.003528185,0.6486555,0.001412583,0.00126523,0.0001229709,0.00009892961,0.000004624247,0.000592148,0.001151036,0.2308549,0.0001387612],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9723498,0.0117545,0.00004796821,0.01375819,0.0003951623,0.000116913,3.4388e-7,0.000007936817,0.001569171],"genre_scores_gemma":[0.9939917,0.003131516,0.0002589196,0.0004347122,0.0007950097,7.333074e-7,6.708083e-7,0.00001033246,0.00137639],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4901447,"threshold_uncertainty_score":0.2005329,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2974260792","doi":"10.1056/nejmoa1911303","title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6873,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Montreal Heart Institute; Libin Cardiovascular Institute of Alberta; St. Michael's Hospital; University of Calgary","funders":"AstraZeneca","keywords":"Dapagliflozin; Ejection fraction; Heart failure; Cardiology; Internal medicine; Fraction (chemistry); Medicine; Chemistry; Diabetes mellitus; Endocrinology; Chromatography","retraction":null,"screen_n_in":null,"score":{"opus":0.005921450203652242,"gpt":0.2270162747503756,"spread":0.2210948245467234,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002494582,0.00008898212,0.0003041449,0.0002320687,0.00001182214,0.000005269987,0.00002054959,0.00003232395,0.0001200607],"category_scores_gemma":[0.00004253081,0.00005141042,0.00001796147,0.000125299,0.00001926604,0.0001302819,0.000006662105,0.0001687583,0.000004859764],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005859444,"about_ca_system_score_gemma":0.00002953803,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003033779,"about_ca_topic_score_gemma":0.0000138564,"domain_scores_codex":[0.9992715,0.00002615849,0.0002187223,0.00009126908,0.0002887885,0.000103558],"domain_scores_gemma":[0.9995565,0.00003737184,0.0001281585,0.00008190188,0.00007872829,0.0001173725],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001311455,0.000122312,0.970643,0.00003564942,0.00008024683,0.00001317881,0.0001124175,0.000006707753,0.0008856452,0.00001428924,0.005537477,0.02123763],"study_design_scores_gemma":[0.07997376,0.005948907,0.8715541,0.0006141206,0.0001892712,0.00003524228,0.0001881248,0.00001255972,0.0001410629,0.00005196125,0.04123404,0.00005681452],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926656,0.0001520367,0.00002487632,0.005794375,0.00024321,0.000238204,1.768655e-7,0.00000591843,0.0008755872],"genre_scores_gemma":[0.9981419,0.00003940918,0.0004855732,0.000300396,0.0005241556,6.780684e-7,0.000007283367,0.000008825229,0.0004917534],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09908886,"threshold_uncertainty_score":0.2096456,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2519510391","doi":"10.1056/nejmoa1607141","title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","year":2016,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6603,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Manitoba; University of Toronto; St. Michael's Hospital","funders":"Servier; Novo Nordisk Fonden; Medicines Company; Novo Nordisk; Intarcia Therapeutics; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Mylan; MannKind Corporation; GlaxoSmithKline","keywords":"Semaglutide; Type 2 diabetes; Medicine; Diabetes mellitus; Internal medicine; Cardiology; Endocrinology; Liraglutide","retraction":null,"screen_n_in":null,"score":{"opus":0.008063027747281284,"gpt":0.2113504001113577,"spread":0.2032873723640764,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004970062,0.0003079358,0.001469393,0.0004660959,0.0000165704,0.000008448258,0.00009727086,0.0001623549,0.0001069065],"category_scores_gemma":[0.0002110521,0.0001402609,0.0001294851,0.0001215291,0.00009953059,0.00005734191,0.00003074032,0.0006238,0.000004735641],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007349998,"about_ca_system_score_gemma":0.00008107373,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001915334,"about_ca_topic_score_gemma":0.000003860372,"domain_scores_codex":[0.9980605,0.00007389581,0.0004601929,0.0002081704,0.0008770467,0.0003201546],"domain_scores_gemma":[0.9988598,0.0002201316,0.0002539412,0.0003052492,0.0001957408,0.0001651688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001931521,0.00003451279,0.5619485,0.0001525294,0.002470959,0.0007461012,0.00006443955,4.843528e-7,0.000001803236,0.000001167206,0.3328839,0.1015025],"study_design_scores_gemma":[0.0683291,0.003321993,0.1937973,0.002021923,0.002172289,0.0000196036,0.000007115811,2.690511e-7,0.000004214843,0.00005690969,0.7301288,0.0001405649],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.4830832,0.008366426,0.000009889119,0.5055591,0.0009909298,0.0005933032,0.000005591276,0.00001601713,0.001375597],"genre_scores_gemma":[0.3292003,0.004239501,0.001291738,0.600768,0.04340801,0.00001448897,0.0002516346,0.0003180106,0.02050837],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.3972449,"threshold_uncertainty_score":0.5719674,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2900413769","doi":"10.1056/nejmoa1812389","title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6310,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"AstraZeneca","keywords":"Dapagliflozin; Mace; Medicine; Hazard ratio; Myocardial infarction; Internal medicine; Type 2 diabetes; Diabetes mellitus; Stroke (engine); Placebo; Cardiology; Heart failure; Confidence interval; Endocrinology; Percutaneous coronary intervention","retraction":null,"screen_n_in":null,"score":{"opus":0.01643180572280189,"gpt":0.2611640940270873,"spread":0.2447322883042854,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007641376,0.0001139908,0.0006157435,0.0002475762,0.00001776244,0.000005743751,0.00005423137,0.00003391769,0.0001392004],"category_scores_gemma":[0.00029778,0.00006604449,0.0000702874,0.0001594415,0.0001059035,0.00006330517,0.00002266736,0.0001235836,0.000006925768],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002473628,"about_ca_system_score_gemma":0.00003903855,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003225719,"about_ca_topic_score_gemma":0.00001770197,"domain_scores_codex":[0.9990562,0.00003903163,0.0003004497,0.000103256,0.0003338718,0.0001671607],"domain_scores_gemma":[0.999385,0.00007805706,0.00007718846,0.0001636081,0.0001111414,0.0001849816],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002414254,0.00008917798,0.5973462,0.00004771899,0.001255324,0.0002411742,0.000661807,0.000002047489,0.0004451796,0.0001033809,0.009550666,0.3900159],"study_design_scores_gemma":[0.09675416,0.008233279,0.5423305,0.0008357381,0.001829848,0.0001406458,0.0002863445,0.00004897358,0.0006248947,0.0009068912,0.34784,0.0001686708],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980701,0.009559094,0.00002533358,0.005495709,0.000611858,0.0001272085,2.356588e-7,0.000008018539,0.003471559],"genre_scores_gemma":[0.9949927,0.001007511,0.0004745529,0.0006706534,0.001981375,5.963311e-7,0.00000174989,0.00001095106,0.0008598602],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3898472,"threshold_uncertainty_score":0.2693217,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2939222610","doi":"10.1056/nejmoa1811744","title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5996,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University of British Columbia","funders":"Janssen Research and Development","keywords":"Canagliflozin; Medicine; Type 2 diabetes; Diabetes mellitus; Diabetic nephropathy; Nephropathy; Dapagliflozin; Internal medicine; Clinical trial; Type 2 Diabetes Mellitus; Endocrinology; Intensive care medicine; Pharmacology; Urology","retraction":null,"screen_n_in":null,"score":{"opus":0.009162856530291195,"gpt":0.2442398749127619,"spread":0.2350770183824707,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004219846,0.0001122323,0.0004821413,0.0002332925,0.00001082989,0.000007010987,0.0000364673,0.00003120857,0.000119992],"category_scores_gemma":[0.0001206351,0.00006550516,0.0000212293,0.0001065386,0.00004729424,0.00007058281,0.0000235351,0.0001454783,0.000003392727],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002802219,"about_ca_system_score_gemma":0.00004406065,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000810499,"about_ca_topic_score_gemma":0.00006590661,"domain_scores_codex":[0.9992234,0.00002814392,0.000278081,0.00009875742,0.0002171514,0.0001544268],"domain_scores_gemma":[0.9994446,0.0001142369,0.0001070535,0.00009071505,0.00004787401,0.0001955178],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002265558,0.00004483818,0.8697754,0.00006495821,0.0001612762,0.0001426996,0.0004846776,0.000001926442,0.001527577,0.000117254,0.002613127,0.1248397],"study_design_scores_gemma":[0.07211217,0.005100267,0.8583611,0.0008543032,0.0004451522,0.00009955551,0.0002904003,0.0000740603,0.0001768429,0.0005757191,0.06178724,0.0001231686],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851967,0.004797038,0.000002530381,0.007912701,0.0003154145,0.0001547655,3.655233e-7,0.000004874653,0.001615589],"genre_scores_gemma":[0.9955014,0.001121332,0.0002419485,0.0009866284,0.0004384117,4.802176e-7,0.000002490779,0.000009419118,0.001697872],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1247166,"threshold_uncertainty_score":0.2671223,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3081830235","doi":"10.1056/nejmoa2022190","title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5037,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Boehringer Ingelheim (Canada); University of Toronto; McGill University Health Centre; St. Michael's Hospital","funders":"Eli Lilly and Company; Boehringer Ingelheim","keywords":"Empagliflozin; Heart failure; Medicine; Ejection fraction; Cardiology; Diabetes mellitus; Internal medicine; Benzhydryl compounds; Broad spectrum; Heart failure with preserved ejection fraction; Type 2 diabetes; Endocrinology; Chemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.01415884499992119,"gpt":0.236561217026782,"spread":0.2224023720268609,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003730367,0.0001278687,0.0006850854,0.0001325831,0.00001378832,0.000006433886,0.00004463607,0.00002857325,0.00006264349],"category_scores_gemma":[0.0001147694,0.00006717023,0.00008088743,0.0001576237,0.00005102872,0.00006794395,0.00001622957,0.0002046426,0.000002160565],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000216377,"about_ca_system_score_gemma":0.00005321517,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003844828,"about_ca_topic_score_gemma":0.00002692061,"domain_scores_codex":[0.9989972,0.00003913396,0.000278711,0.0001168507,0.0004264011,0.0001417128],"domain_scores_gemma":[0.9993855,0.00005282484,0.00007455696,0.0001039447,0.00005141409,0.0003316967],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001549885,0.0001095821,0.8494911,0.0001715763,0.002645425,0.002392239,0.0026037,0.0001258773,0.0007858808,0.00009619696,0.04426388,0.09576467],"study_design_scores_gemma":[0.1568662,0.007108022,0.2366066,0.0008757188,0.001934012,0.000615188,0.0006808977,0.00003785524,0.0002545254,0.00008782508,0.5947765,0.0001567163],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8578954,0.004708061,0.000266842,0.1361838,0.00007706907,0.000212208,4.772132e-7,0.0000117281,0.0006444458],"genre_scores_gemma":[0.9937358,0.000215338,0.002204399,0.002606008,0.001059465,0.000001068273,0.000002516586,0.00001272131,0.0001627175],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6128845,"threshold_uncertainty_score":0.2739123,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3127371223","doi":"10.1056/nejmoa2032183","title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4502,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; York University","funders":"Steno Diabetes Center Aarhus; Novo Nordisk Fonden; Novo Nordisk; National Institute for Health and Care Research","keywords":"Semaglutide; Obesity; Overweight; Medicine; Weight loss; Intervention (counseling); Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes; Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.01218362546999398,"gpt":0.2496546729605695,"spread":0.2374710474905755,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003776129,0.0001544492,0.000572759,0.0001825753,0.00002163943,0.000006742333,0.00007049223,0.00004097513,0.0007182449],"category_scores_gemma":[0.0002221943,0.00007911464,0.00005155083,0.0003289701,0.00005345425,0.00007440302,0.00002303235,0.0002556754,0.000006676252],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001001754,"about_ca_system_score_gemma":0.0003180518,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008132705,"about_ca_topic_score_gemma":0.0005039642,"domain_scores_codex":[0.9986526,0.00005400137,0.0004137002,0.0001493149,0.0005106749,0.0002197341],"domain_scores_gemma":[0.9990355,0.00012941,0.0001880813,0.0001802931,0.0001796604,0.0002870634],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0150017,0.001774102,0.4356933,0.0006141577,0.001023617,0.04686407,0.004273663,0.00004500488,0.0008975891,0.0006072829,0.06289327,0.4303123],"study_design_scores_gemma":[0.330751,0.01515939,0.3470943,0.01195511,0.001359813,0.00420523,0.002154448,0.00007546522,0.002139362,0.0006022327,0.2841924,0.0003113248],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9695728,0.002339478,0.0001674526,0.01760162,0.0003063475,0.0001780218,9.526942e-7,0.00001207924,0.009821188],"genre_scores_gemma":[0.9814919,0.001101433,0.0026199,0.001491462,0.002001248,0.000001566536,0.0000115788,0.00001781774,0.01126315],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4300009,"threshold_uncertainty_score":0.7864278,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2111876001","doi":"10.1007/s00125-012-2534-0","title":"Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","year":2012,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3932,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Abbott Diabetes Care; Novartis Pharma; University of Illinois at Urbana-Champaign; Servier; Université de Nantes; European Association for the Study of Diabetes; Novo Nordisk; University of Melbourne; University of Southern California; University of Sydney; Health Science Center, University of Tennessee; National Institute for Health and Care Research; National Institutes of Health; School of Medicine, Case Western Reserve University; Dexcom; Leonard M. Miller School of Medicine, University of Miami; Georgetown University; Intarcia Therapeutics; American Diabetes Association; MedStar Health Research Institute; Leona M. and Harry B. Helmsley Charitable Trust; F. Hoffmann-La Roche; Wayne State University; Leonard M. Miller School of Medicine; University of Toronto; Yale University; GlaxoSmithKline; Bristol-Myers Squibb; Eli Lilly and Company; School of Medicine, University of Kansas; Pfizer; University of Miami; AstraZeneca; Halozyme; Case Western Reserve University; University of Ioannina; Amylin Pharmaceuticals; Sanofi","keywords":"Diabetes mellitus; Position statement; Medicine; Association (psychology); Type 2 diabetes; Human physiology; Endocrinology; Internal medicine; Gerontology; Family medicine; Psychology","retraction":null,"screen_n_in":null,"score":{"opus":0.01362830247586919,"gpt":0.2396161366155795,"spread":0.2259878341397104,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002233399,0.0002115894,0.0006301705,0.0001035045,0.00009179791,0.00001696397,0.0002112359,0.00004259107,0.000002916271],"category_scores_gemma":[0.0002738748,0.0001135258,0.0001419784,0.0004893622,0.0001449419,0.00009830307,0.0002130981,0.0001210609,9.968284e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002497702,"about_ca_system_score_gemma":0.00001163969,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001800069,"about_ca_topic_score_gemma":0.000006255437,"domain_scores_codex":[0.9974725,0.0006466182,0.0006619074,0.0002273906,0.0005242312,0.0004673487],"domain_scores_gemma":[0.997343,0.0007575966,0.001271405,0.0004166072,0.0001704889,0.00004087283],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00009653132,0.001719006,0.9801497,0.0002738768,0.001862792,1.392205e-7,0.001486413,0.00003980888,0.0003686503,0.0002209339,0.0002981474,0.01348397],"study_design_scores_gemma":[0.004637648,0.0009720442,0.9859532,0.000135253,0.001696882,1.456738e-8,0.003526714,0.0004533514,0.002255181,0.00006484767,0.0001918801,0.0001130277],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942194,0.000875796,0.000006284658,0.000511767,0.0002145073,0.003300701,0.00003030936,0.00001782342,0.0008234223],"genre_scores_gemma":[0.9990582,0.0001217613,0.0001497416,0.0001577749,0.00003009208,0.0003192605,0.00004530738,0.00002428694,0.00009351065],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01337094,"threshold_uncertainty_score":0.462945,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2159205789","doi":"10.1016/s0140-6736(06)69705-5","title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","year":2006,"lang":"en","type":"review","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3875,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Deutsche Diabetes Gesellschaft; Canada Research Chairs; Juvenile Diabetes Research Foundation Canada; Canadian Diabetes Association; Deutsche Forschungsgemeinschaft; Eli Lilly and Company","keywords":"Vildagliptin; Incretin; Exenatide; Liraglutide; Sitagliptin; Medicine; Type 2 diabetes; Internal medicine; Endocrinology; Glucagon-like peptide-1; Dipeptidyl peptidase-4; Pharmacology; Glucagon-like peptide 1 receptor; Gastric emptying; Diabetes mellitus; Receptor; Agonist","retraction":null,"screen_n_in":null,"score":{"opus":0.02699947715974299,"gpt":0.2865942634395749,"spread":0.259594786279832,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001119229,0.0005882277,0.002253867,0.0001452912,0.0002359979,0.0001798939,0.0004546712,0.0002217984,0.0000154581],"category_scores_gemma":[0.00008658117,0.0002905237,0.0002640805,0.0004930302,0.0002408192,0.00005422223,0.0002969821,0.000536911,0.000298363],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003180972,"about_ca_system_score_gemma":0.0001086752,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006915364,"about_ca_topic_score_gemma":0.00005836953,"domain_scores_codex":[0.9973335,0.0003490011,0.0007050188,0.0005049995,0.0003592062,0.000748319],"domain_scores_gemma":[0.9978718,0.0005101066,0.0003720862,0.001092494,0.00005061309,0.000102943],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006474151,0.0001078678,0.00140027,0.02488003,0.0007161153,0.00003855212,0.00009428817,3.986291e-7,0.000003086126,0.0008452157,0.3068169,0.6650325],"study_design_scores_gemma":[0.0008447148,0.0001611294,0.0002701457,0.01683661,0.001139708,0.000005144388,0.00007999168,0.000006436247,0.000003077139,0.0000170525,0.9803441,0.0002919299],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00267528,0.9809056,1.658872e-7,0.0006495366,0.0007619738,0.002159327,0.00004618791,0.0001435742,0.01265835],"genre_scores_gemma":[0.0007529557,0.9890808,0.00007175076,0.0002172944,0.001689009,0.0004001488,0.0004166525,0.00009744587,0.007273902],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6735271,"threshold_uncertainty_score":0.9999547,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2146901298","doi":"10.2337/dc08-9025","title":"Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy","year":2008,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3837,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Insulet Corporation; Novo Nordisk; Sanofi; GlaxoSmithKline; Servier; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psychological intervention; Algorithm; Consensus algorithm; Diabetes mellitus; Type 2 diabetes; Intensive care medicine; MEDLINE; Diabetes management; Computer science; Nursing","retraction":null,"screen_n_in":null,"score":{"opus":0.02024918920528253,"gpt":0.2630219083756123,"spread":0.2427727191703297,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001355621,0.0001326967,0.0003199386,0.00009666251,0.00003196521,0.000002264583,0.00007556229,0.00006444739,0.00003110029],"category_scores_gemma":[0.00002574181,0.00009072897,0.00007255365,0.0001855129,0.0001455621,0.00002077916,0.00004860292,0.00005598097,0.000002247339],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004265031,"about_ca_system_score_gemma":0.00003881021,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000004908367,"about_ca_topic_score_gemma":0.000002523953,"domain_scores_codex":[0.9990073,0.00002430453,0.0002791908,0.0001778888,0.0002976911,0.0002136679],"domain_scores_gemma":[0.9993215,0.000193134,0.00009020008,0.0002137321,0.0001236124,0.00005785451],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.00008516773,0.0002889736,0.2626185,0.0006551089,0.0006727704,0.00001277247,0.00096267,0.000005593289,0.0001501007,0.0001922861,0.0007707672,0.7335852],"study_design_scores_gemma":[0.0138571,0.002491682,0.9577616,0.0009140084,0.0005961162,0.000001343814,0.003577755,0.004162336,0.01051759,0.0001104578,0.005750967,0.0002590614],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.979582,0.01821942,0.00001223449,0.0002804656,0.000144624,0.001222908,0.00003020609,0.00001621392,0.0004919632],"genre_scores_gemma":[0.9917926,0.005754306,0.001676397,0.0003751445,0.00004011532,0.0001927375,0.0000989967,0.00001753959,0.00005222517],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7333262,"threshold_uncertainty_score":0.369982,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2424539745","doi":"10.1056/nejmoa1515920","title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3629,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Empagliflozin; Medicine; Placebo; Hazard ratio; Internal medicine; Diabetes mellitus; Albuminuria; Renal function; Type 2 diabetes; Diabetic nephropathy; Creatinine; Kidney disease; Urology; Surgery; Confidence interval; Endocrinology; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.01207844112599694,"gpt":0.278069689627907,"spread":0.2659912485019101,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003967784,0.00008957966,0.0003448829,0.0002124915,0.000007953054,0.000001938814,0.00004356347,0.00002255167,0.0001480653],"category_scores_gemma":[0.000872491,0.00004033582,0.00002809741,0.0001154892,0.00008104275,0.00006745246,0.00001987137,0.00006272017,0.000001481005],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002337937,"about_ca_system_score_gemma":0.0001152615,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000004863249,"about_ca_topic_score_gemma":0.000001667485,"domain_scores_codex":[0.9991751,0.00003383621,0.0003204728,0.00007924057,0.0002643931,0.0001269706],"domain_scores_gemma":[0.9990196,0.00009442979,0.0001673228,0.00009810317,0.0000826162,0.0005379295],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0009160674,0.0001239427,0.5755192,0.0001153323,0.00009006257,0.0001287195,0.000176248,2.408909e-7,0.005074875,0.00007951885,0.01143945,0.4063363],"study_design_scores_gemma":[0.1619032,0.009851316,0.658083,0.01452837,0.001132511,0.00003136157,0.0000804178,0.00003167509,0.003476411,0.002322565,0.1483784,0.0001808385],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9695873,0.00455693,0.00001490931,0.02492869,0.0002534427,0.000141001,0.000001177718,0.000004839272,0.0005117552],"genre_scores_gemma":[0.9966446,0.001483865,0.0002428624,0.0004146205,0.0006129575,8.54708e-7,0.000002584369,0.000008117016,0.0005895528],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4061555,"threshold_uncertainty_score":0.1644847,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2084948079","doi":"10.1053/j.gastro.2007.03.054","title":"Biology of Incretins: GLP-1 and GIP","year":2007,"lang":"en","type":"review","venue":"Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3573,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Incretin; Medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes","retraction":null,"screen_n_in":null,"score":{"opus":0.04515121845514113,"gpt":0.3502311483063948,"spread":0.3050799298512537,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002096103,0.0002757394,0.001786296,0.0003530613,0.00001303404,0.000002556922,0.00009307227,0.0002277592,0.00008375911],"category_scores_gemma":[0.00002468989,0.0002029634,0.0002316916,0.00007438188,0.0002105222,0.00001225392,0.0001683731,0.0001748017,0.00002595695],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003749691,"about_ca_system_score_gemma":0.00002290526,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000121603,"about_ca_topic_score_gemma":0.0000087256,"domain_scores_codex":[0.9986725,0.00009237276,0.0004805131,0.0003236014,0.00006102471,0.0003700222],"domain_scores_gemma":[0.999267,0.00006128237,0.0002577849,0.0002911976,0.00002795279,0.00009477519],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000800298,0.0001174734,0.009334792,0.007958765,0.0008790712,0.00004173139,0.00001170816,3.587507e-9,9.845235e-7,0.0003291316,0.0006530817,0.9805932],"study_design_scores_gemma":[0.0008879199,0.002099187,0.0004978749,0.001711524,0.00203127,0.0001004978,0.000003641691,2.584709e-7,7.602086e-7,0.00002452144,0.9925815,0.00006105789],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001698859,0.9958103,0.00006566547,0.00006053452,0.0001735022,0.0006361777,0.00002632982,0.00002715287,0.001501509],"genre_scores_gemma":[0.0003074852,0.9979533,0.0007199872,0.0002695024,0.00009902914,0.00004398757,0.000274071,0.00002715531,0.0003054977],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9919284,"threshold_uncertainty_score":0.8276608,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2064130493","doi":"10.1056/nejmoa1307684","title":"Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus","year":2013,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3474,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Saxagliptin; Medicine; Hazard ratio; Myocardial infarction; Internal medicine; Heart failure; Placebo; Stroke (engine); Type 2 diabetes; Unstable angina; Clinical endpoint; Diabetes mellitus; Confidence interval; Randomized controlled trial; Sitagliptin; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.006977232647670703,"gpt":0.2072257417869228,"spread":0.2002485091392521,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003319191,0.0001324161,0.0006262974,0.0001996905,0.00001392345,0.000008925875,0.00004736915,0.00002964203,0.0001638729],"category_scores_gemma":[0.0001238601,0.00006732626,0.00005207207,0.0001289948,0.00005299599,0.0001056553,0.00001617936,0.0001314546,0.000006490661],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002771999,"about_ca_system_score_gemma":0.00002784164,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007706477,"about_ca_topic_score_gemma":0.000006816652,"domain_scores_codex":[0.9989723,0.00003475772,0.0002852596,0.0001044738,0.0004259546,0.0001772399],"domain_scores_gemma":[0.9993191,0.0000689994,0.00009749979,0.0001543842,0.0001526997,0.0002072935],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001137039,0.00009865862,0.7930367,0.00002707625,0.0006918985,0.00002825345,0.0001794277,0.000004730692,0.00001337849,0.0000108888,0.001707746,0.2040875],"study_design_scores_gemma":[0.05794384,0.003260334,0.9235664,0.0003136739,0.0005993749,0.000006264318,0.00006705069,0.000005965953,0.00002399598,0.0001125274,0.01402896,0.00007162297],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912513,0.005409061,0.000008389206,0.001970259,0.0001977989,0.0002870148,2.812988e-7,0.000006271186,0.0008695979],"genre_scores_gemma":[0.9979237,0.0004868134,0.0004872884,0.0003690014,0.0003406792,0.000001774122,0.000005495473,0.00001267544,0.0003725408],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2040159,"threshold_uncertainty_score":0.2745485,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2172193326","doi":"10.2337/dc12-0413","title":"Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach","year":2012,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3218,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Leonard M. Miller School of Medicine, University of Miami; Leonard M. Miller School of Medicine; Health Science Center, University of Tennessee; University of Illinois at Urbana-Champaign; University of Melbourne; European Association for the Study of Diabetes; National Institute for Health and Care Research; MedStar Health Research Institute; School of Medicine, University of Kansas; University of Ioannina; University of Sydney; School of Medicine, Case Western Reserve University; Université de Nantes; Georgetown University; University of Toronto; Case Western Reserve University; Yale University; Wayne State University; University of Miami; University of Southern California","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; MEDLINE; Intensive care medicine; Diabetes management; Internal medicine; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.03651142278663767,"gpt":0.2767054805289316,"spread":0.2401940577422939,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001210406,0.0007064256,0.00253995,0.000565726,0.00002880291,0.00002128076,0.000291692,0.0003134641,0.00008398157],"category_scores_gemma":[0.000009862175,0.0005685437,0.0006491098,0.0008301593,0.00007107386,0.00009151213,0.0003376645,0.0002982373,0.0002618065],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004137335,"about_ca_system_score_gemma":0.00006054366,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000001747758,"about_ca_topic_score_gemma":5.898778e-7,"domain_scores_codex":[0.9970734,0.0001032665,0.0008763139,0.000632071,0.0004424874,0.0008724328],"domain_scores_gemma":[0.9983296,0.00004712596,0.0003890129,0.0009337922,0.000101522,0.0001989681],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001041236,0.0005642365,0.01536822,0.1143947,0.001414462,0.00001766226,0.0002275736,4.314868e-7,2.889778e-7,0.00005542848,0.0003089642,0.8676376],"study_design_scores_gemma":[0.00125976,0.0004414214,0.0007513694,0.02682001,0.007252405,4.634177e-7,0.0005901718,0.000004670982,0.00000946728,0.000003658098,0.962352,0.0005146556],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00603604,0.9745248,2.441679e-7,0.00000433638,0.0004565674,0.00287352,0.0001032093,0.00007239873,0.01592891],"genre_scores_gemma":[0.009398214,0.984997,0.0008546707,0.00006119749,0.00009078677,0.0007012064,0.00344976,0.0001431354,0.0003039858],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.962043,"threshold_uncertainty_score":0.9996766,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4281934192","doi":"10.1056/nejmoa2206038","title":"Tirzepatide Once Weekly for the Treatment of Obesity","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3207,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; York University","funders":"Eli Lilly and Company","keywords":"Obesity; Agonist; Medicine; Glucagon-like peptide-1; Endocrinology; Diabetes mellitus; Receptor; Internal medicine; Disease; Type 2 diabetes","retraction":null,"screen_n_in":null,"score":{"opus":0.02657164938863743,"gpt":0.2838889725144743,"spread":0.2573173231258368,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005066027,0.0001006975,0.0004048607,0.0001045402,0.0000918275,0.000002364469,0.00009864768,0.00001168894,0.0003291187],"category_scores_gemma":[0.00007258871,0.00004950901,0.0001333787,0.0001160274,0.00004919769,0.00002587944,0.00001618096,0.00007905954,6.899924e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001344565,"about_ca_system_score_gemma":0.00009119629,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009675004,"about_ca_topic_score_gemma":0.00001468802,"domain_scores_codex":[0.999011,0.00004104986,0.0003515065,0.00007657777,0.0003904118,0.0001294419],"domain_scores_gemma":[0.9989547,0.0004039666,0.0002836555,0.0001635462,0.00008661733,0.0001075788],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002499898,0.001222288,0.02846654,0.00006783432,0.00132984,0.0001413489,0.0030846,0.0002120782,0.0009752967,0.0006639704,0.04752365,0.9138126],"study_design_scores_gemma":[0.07084417,0.02601737,0.01529595,0.00009668643,0.001934954,0.0001287487,0.0009438248,0.0001701963,0.0006949934,0.0005350632,0.8832796,0.000058506],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.940551,0.01123458,0.001486138,0.04214491,0.00128603,0.000977693,0.00001127095,0.00001254666,0.00229581],"genre_scores_gemma":[0.9888886,0.001568035,0.000826593,0.0004866756,0.001798788,0.0000180245,0.00001059183,0.00001234598,0.006390414],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9137542,"threshold_uncertainty_score":0.3603619,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2948612418","doi":"10.1016/s0140-6736(19)31149-3","title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3040,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Michael's Hospital; Institut universitaire de cardiologie et de pneumologie de Québec; Population Health Research Institute; Université Laval; University of Toronto; Hamilton Health Sciences; McMaster University","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Type 2 diabetes; Internal medicine; Clinical endpoint; Placebo; Population; Myocardial infarction; Diabetes mellitus; Stroke (engine); Adverse effect; Semaglutide; Randomized controlled trial; Physical therapy; Exenatide; Liraglutide; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.02643249314968423,"gpt":0.2691027811706797,"spread":0.2426702880209955,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001017627,0.0001672744,0.001419335,0.00008391367,0.00002924647,0.00003273651,0.000115837,0.00005230821,0.00008947516],"category_scores_gemma":[0.00007917617,0.00009100845,0.0002558419,0.0001208787,0.00003250803,0.00004910458,0.00005901691,0.0001203511,0.00009958049],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002716719,"about_ca_system_score_gemma":0.00002262799,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002148935,"about_ca_topic_score_gemma":0.000008406089,"domain_scores_codex":[0.9988876,0.0001010007,0.0002299152,0.0002224408,0.0002406185,0.0003183973],"domain_scores_gemma":[0.9990351,0.0002213358,0.00005112677,0.0006217998,0.00002170488,0.00004888946],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9380876,0.0001383138,0.05607112,0.00006289435,0.002841264,0.00001139347,0.0001341031,0.00003396296,0.00005417127,0.00020293,0.000859996,0.001502289],"study_design_scores_gemma":[0.9857284,0.0003175514,0.008115361,0.00004283193,0.0008311091,4.632757e-7,0.00003838495,0.0001313349,0.00008424298,0.00008498526,0.004519236,0.0001060919],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9776249,0.002366716,8.924582e-7,0.00156121,0.0003804817,0.006934037,0.000001442781,0.00004763384,0.01108269],"genre_scores_gemma":[0.9952622,0.0002391342,0.00004752165,0.0005234146,0.000301396,0.0004194035,0.00001285479,0.00001790436,0.003176189],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04795576,"threshold_uncertainty_score":0.3711217,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2899764361","doi":"10.1016/s0140-6736(18)32590-x","title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","year":2018,"lang":"en","type":"review","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2818,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Internal medicine; Heart failure; Hazard ratio; Meta-analysis; Diabetes mellitus; Stroke (engine); Myocardial infarction; Adverse effect; Renal function; Disease; Cardiology; Placebo; Type 2 diabetes; Proportional hazards model; Clinical trial; Intensive care medicine; Confidence interval; Endocrinology; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1495659311323261,"gpt":0.3679194309269754,"spread":0.2183534997946493,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.008989348,0.0003821615,0.02612298,0.0003350035,0.00002419682,0.00001655641,0.0001381662,0.0001181221,0.00001328096],"category_scores_gemma":[0.0006237485,0.0001866152,0.005739459,0.0004438944,0.0001055861,0.00005091364,0.0001280935,0.0001148707,6.112402e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004047129,"about_ca_system_score_gemma":0.00004488861,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001281491,"about_ca_topic_score_gemma":0.000003478265,"domain_scores_codex":[0.9962637,0.001080494,0.001712588,0.0003957714,0.0003452551,0.0002021881],"domain_scores_gemma":[0.9972117,0.0006136319,0.0008619397,0.00117239,0.00009294005,0.00004742674],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.000006191994,0.00002422857,0.00004846356,0.5372134,0.4551339,0.000001021836,0.00001631693,3.674354e-7,3.639418e-8,0.000009347206,0.00009941961,0.007447306],"study_design_scores_gemma":[0.0009944296,0.0001615351,0.0001037737,0.0256744,0.9222555,0.00000144957,0.000006385977,0.000001453201,7.385416e-7,0.0000203526,0.05064139,0.0001386098],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002071653,0.991816,0.00001220176,0.00007075415,0.00003733304,0.007601087,0.0001810513,0.000009866008,0.00006458318],"genre_scores_gemma":[0.00007861188,0.9983039,0.0002479677,0.00009916896,0.00005379524,0.0007789378,0.0001637093,0.00002770914,0.0002461802],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.511539,"threshold_uncertainty_score":0.9883353,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4293354639","doi":"10.1056/nejmoa2206286","title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2658,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; St. Michael's Hospital; Université de Montréal; Montreal Heart Institute","funders":"AstraZeneca","keywords":"Ejection fraction; Dapagliflozin; Heart failure; Cardiology; Internal medicine; Medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes","retraction":null,"screen_n_in":null,"score":{"opus":0.02018025195684804,"gpt":0.2702930429826849,"spread":0.2501127910258368,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007592986,0.0001215222,0.0004063906,0.0003860091,0.00006110953,0.000006776328,0.00006964275,0.00002609233,0.001205457],"category_scores_gemma":[0.000124226,0.00007033641,0.00004300828,0.0003879072,0.00002663111,0.0001275572,0.00002493704,0.000406565,0.000002545326],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002021508,"about_ca_system_score_gemma":0.0001453719,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001532998,"about_ca_topic_score_gemma":0.0001449943,"domain_scores_codex":[0.9986357,0.0001201121,0.0003626183,0.0001299795,0.0005835724,0.0001679786],"domain_scores_gemma":[0.9993248,0.00008840446,0.0002096453,0.0001431536,0.00007435394,0.0001596383],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.03077891,0.001492618,0.3096511,0.0002161474,0.001067181,0.00233462,0.001798193,0.001231717,0.02407812,0.00008862378,0.5561615,0.07110127],"study_design_scores_gemma":[0.1177908,0.01712011,0.06976616,0.0005839263,0.0006397887,0.00110176,0.00258492,0.0001287162,0.0008744301,0.0001454935,0.789118,0.0001458286],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9600585,0.0004541653,0.0001101882,0.03733315,0.0004409676,0.0003521588,8.086213e-7,0.00001761005,0.001232491],"genre_scores_gemma":[0.993057,0.000074323,0.001242773,0.0007745069,0.001449103,0.00001118064,0.00001618148,0.00001786904,0.003357108],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.239885,"threshold_uncertainty_score":0.9997076,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W807162506","doi":"10.1056/nejmoa1411892","title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2594,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Liraglutide; Randomized controlled trial; Weight management; Medicine; Weight loss; Internal medicine; Endocrinology; Type 2 diabetes; Diabetes mellitus; Obesity","retraction":null,"screen_n_in":null,"score":{"opus":0.01928051443918787,"gpt":0.2783272884165796,"spread":0.2590467739773917,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004273798,0.0001616402,0.00255635,0.0006094527,0.00000602385,0.000002258735,0.0001138229,0.00004430669,0.0001007366],"category_scores_gemma":[0.0007915496,0.00008553712,0.0002789754,0.0002129066,0.000126251,0.00005590441,0.00002881035,0.0001450586,0.000001678053],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005864695,"about_ca_system_score_gemma":0.0001164264,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005588882,"about_ca_topic_score_gemma":0.000009626136,"domain_scores_codex":[0.9972191,0.0002231682,0.001505006,0.00009939828,0.00078446,0.0001688635],"domain_scores_gemma":[0.9980611,0.000401693,0.0008972356,0.0001830994,0.0002135839,0.0002432543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.950091,0.0004986925,0.0006226543,0.0001063688,0.001484816,0.0003466147,0.0006229723,0.00001833051,0.00005413172,0.001230112,0.005585059,0.03933926],"study_design_scores_gemma":[0.9813442,0.004266522,0.0001589942,0.0009677716,0.002420311,0.00003785513,0.0002245222,0.00007329172,0.0001331802,0.001528917,0.008788611,0.00005584032],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9095207,0.006909672,0.0005078487,0.008454512,0.001766067,0.003902302,7.836036e-7,0.000009590152,0.06892857],"genre_scores_gemma":[0.9925379,0.001770352,0.001150432,0.0001758352,0.001364252,0.00001796112,0.000003113111,0.00001267052,0.002967495],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08301723,"threshold_uncertainty_score":0.3488103,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2142830692","doi":"10.1056/nejmoa1501352","title":"Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2590,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Canadian VIGOUR Centre; St. Michael's Hospital; University of Alberta","funders":"South Australian Health and Medical Research Institute","keywords":"Sitagliptin; Medicine; Semaglutide; Placebo; Hazard ratio; Sitagliptin Phosphate; Myocardial infarction; Internal medicine; Glycated hemoglobin; Alogliptin; Glycemic; Type 2 diabetes; Relative risk; Confidence interval; Diabetes mellitus; Dipeptidyl peptidase-4 inhibitor; Heart failure; Endocrinology; Insulin; Liraglutide","retraction":null,"screen_n_in":null,"score":{"opus":0.01762287983744475,"gpt":0.2752469197992141,"spread":0.2576240399617694,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002093014,0.0001374325,0.0009770698,0.0003040815,0.000006035498,0.000002374603,0.00007528443,0.00003882731,0.00003652572],"category_scores_gemma":[0.0009930956,0.00007270588,0.0001537964,0.0001813457,0.00004077546,0.00004199519,0.00001589663,0.0001593142,0.000007473715],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006392514,"about_ca_system_score_gemma":0.00005412106,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003117553,"about_ca_topic_score_gemma":0.000003338222,"domain_scores_codex":[0.9986256,0.0001321219,0.0003801941,0.00008901383,0.0006171462,0.0001559471],"domain_scores_gemma":[0.9990423,0.0002675968,0.0001468835,0.0002017714,0.0001156846,0.0002257034],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.002090315,0.0002266967,0.5847603,0.000188326,0.001916554,0.0004634369,0.0006118033,0.0002175994,0.000398246,0.00005696037,0.009565106,0.3995047],"study_design_scores_gemma":[0.4822668,0.1209376,0.2032342,0.003898778,0.006563797,0.0001067952,0.0003466567,0.0000988092,0.01225571,0.0005027934,0.1694166,0.0003713777],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883387,0.005359448,0.000006643957,0.00192349,0.0006419109,0.0001987761,3.283985e-7,0.000006493539,0.003524222],"genre_scores_gemma":[0.998283,0.0001960587,0.00009578887,0.0001892509,0.0007490491,0.000001036951,0.000003421889,0.00001194332,0.0004704465],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4801765,"threshold_uncertainty_score":0.296486,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2806521060","doi":"10.1186/s12933-018-0728-6","title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017","year":2018,"lang":"en","type":"review","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2348,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Barrie Urology Group; University of Toronto","funders":"Novo Nordisk; American Diabetes Association","keywords":"Medicine; Angiology; Type 2 diabetes; Disease; Diabetes mellitus; Systematic review; MEDLINE; Scientific literature; Intensive care medicine; Internal medicine; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.03919924751054406,"gpt":0.3184236154855464,"spread":0.2792243679750023,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006827869,0.0007799471,0.009105277,0.0006787749,0.0000652685,0.00005478259,0.001147744,0.0003233495,0.000046374],"category_scores_gemma":[0.002343668,0.0005022446,0.005853877,0.003070332,0.0008357984,0.0001792485,0.0005093,0.0005628225,0.00007497225],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002890254,"about_ca_system_score_gemma":0.0004240759,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002364313,"about_ca_topic_score_gemma":0.00001333698,"domain_scores_codex":[0.9920321,0.002487388,0.002001083,0.001431288,0.001225667,0.0008224524],"domain_scores_gemma":[0.9919524,0.0008098617,0.0007342192,0.005780601,0.0005310499,0.0001919095],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.00001228442,0.0001459653,0.001811518,0.949371,0.01461008,0.0002889415,0.0001225092,0.0000116449,1.353655e-7,0.000006552506,0.0006934877,0.03292583],"study_design_scores_gemma":[0.0004497799,0.0000569144,0.0008451314,0.761313,0.03694923,0.000005494099,0.000006427585,0.00001133395,0.000002871549,0.000009246717,0.2000522,0.0002983693],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001713278,0.9895488,0.000003869847,0.00002537039,0.001171338,0.00725179,0.0001805453,0.00002490981,0.0000800741],"genre_scores_gemma":[0.0006724623,0.9970511,0.00006410291,0.00004753777,0.0001711612,0.001227794,0.0002694246,0.00007260642,0.0004237856],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.1993587,"threshold_uncertainty_score":0.9997429,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2282578582","doi":"10.1056/nejmoa1509225","title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2338,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Montreal Heart Institute; McMaster University","funders":"","keywords":"Lixisenatide; Acute coronary syndrome; Type 2 diabetes; Medicine; Internal medicine; Cardiology; Diabetes mellitus; Myocardial infarction; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.01195236518700724,"gpt":0.2354445091150264,"spread":0.2234921439280191,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003047607,0.0001134673,0.0003973584,0.0002087363,0.000009869111,0.000004882317,0.0000456646,0.00002655361,0.00003709123],"category_scores_gemma":[0.00009064702,0.00006208635,0.00001449255,0.0001506006,0.0000564009,0.0001023621,0.00001982097,0.0001325866,0.000002890903],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005310738,"about_ca_system_score_gemma":0.00007094292,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008673207,"about_ca_topic_score_gemma":0.000005600839,"domain_scores_codex":[0.999113,0.00002617579,0.0002485295,0.00008688997,0.0003752592,0.0001501941],"domain_scores_gemma":[0.9992645,0.00004933308,0.0001272585,0.00008976673,0.0001484551,0.0003206658],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001081329,0.0001437771,0.9527619,0.00002198184,0.0003280181,0.0007010677,0.0003961524,0.000003052133,0.00001702879,0.00001662231,0.005538503,0.0389905],"study_design_scores_gemma":[0.09334512,0.01374849,0.8855426,0.0005532715,0.0005159183,0.0001546356,0.00008745285,0.000009629537,0.00001526597,0.000193869,0.005763207,0.00007053892],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951671,0.001251725,0.000004022524,0.002316402,0.0002342142,0.000164969,5.586683e-7,0.000006468816,0.0008544763],"genre_scores_gemma":[0.9980648,0.0001495868,0.0004707497,0.0004782691,0.0001980465,6.834067e-7,0.00001297988,0.00001186156,0.0006130768],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09226379,"threshold_uncertainty_score":0.2531808,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2032322539","doi":"10.1016/j.cmet.2006.01.004","title":"The biology of incretin hormones","year":2006,"lang":"en","type":"review","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2164,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Incretin; Hormone; Biology; Glucagon-like peptide-1; Computational biology; Bioinformatics; Endocrinology; Internal medicine; Cell biology; Medicine; Diabetes mellitus; Type 2 diabetes","retraction":null,"screen_n_in":null,"score":{"opus":0.02483561422263736,"gpt":0.3044147166328629,"spread":0.2795791024102255,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002436365,0.0002825512,0.001553822,0.0001278015,0.00004901145,0.00001092051,0.0001979317,0.000168364,0.0000303173],"category_scores_gemma":[0.00002494785,0.0001422953,0.0005049091,0.000191168,0.0001220575,0.00001168624,0.0001092623,0.0001495368,0.0001181905],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001853108,"about_ca_system_score_gemma":0.00006801906,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003038223,"about_ca_topic_score_gemma":0.000001253956,"domain_scores_codex":[0.9988185,0.0001089078,0.0004746829,0.0002293502,0.0001131303,0.0002553966],"domain_scores_gemma":[0.9989074,0.0001637178,0.000331425,0.0005093971,0.0000401686,0.00004789873],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00000317591,0.00006836351,0.000004501218,0.00388235,0.0002705976,0.000003853246,0.000004650757,8.810392e-9,0.000004556613,0.003682358,0.007458063,0.9846175],"study_design_scores_gemma":[0.0003122275,0.00004294798,0.00002653903,0.0005768127,0.004948584,0.000001294347,0.000003907316,2.018944e-7,0.00004030617,0.0001356216,0.9938008,0.0001107843],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00002252021,0.9559385,0.000003987126,0.00003560012,0.0004091541,0.000810423,0.0000171567,0.00002660376,0.04273606],"genre_scores_gemma":[0.00002091785,0.9843807,0.0001795742,0.00002162464,0.0002934324,0.0001168669,0.0002294007,0.00003572953,0.01472176],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9863427,"threshold_uncertainty_score":0.5802634,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2754041380","doi":"10.1056/nejmoa1612917","title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2143,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Duke Clinical Research Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Exenatide; Hazard ratio; Myocardial infarction; Placebo; Interquartile range; Internal medicine; Stroke (engine); Diabetes mellitus; Type 2 diabetes; Heart failure; Confidence interval; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.01492942373253294,"gpt":0.2697077822158324,"spread":0.2547783584832994,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007453165,0.0001480517,0.0009747983,0.0002582997,0.00003273326,0.000007819172,0.0001723147,0.0000432266,0.00003104145],"category_scores_gemma":[0.001283135,0.00008557183,0.0001818476,0.00006615783,0.00008535244,0.00008140564,0.00003001485,0.0001866186,0.000004614805],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005136251,"about_ca_system_score_gemma":0.00005304724,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007411666,"about_ca_topic_score_gemma":0.000009536194,"domain_scores_codex":[0.998692,0.00005235796,0.0003859957,0.0001101689,0.0005783365,0.0001811766],"domain_scores_gemma":[0.9987625,0.0002635098,0.0003240306,0.0003796488,0.000107927,0.0001623899],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.000643008,0.0004557027,0.4117888,0.0004129132,0.002691382,0.001033826,0.0004956142,0.00004257217,0.001791818,0.0002015807,0.005098999,0.5753438],"study_design_scores_gemma":[0.09500932,0.007094293,0.8521058,0.002689455,0.001698754,0.00001565528,0.00004993496,0.00001981549,0.006525853,0.0004175005,0.03425569,0.0001179266],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9857139,0.004250703,0.000009663212,0.004948367,0.0008574887,0.0002458807,3.221338e-7,0.000005563974,0.003968119],"genre_scores_gemma":[0.9965016,0.001069402,0.0001864966,0.0002526635,0.000835461,0.000001588769,0.000001622912,0.00001359722,0.001137562],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5752259,"threshold_uncertainty_score":0.3489518,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4206445899","doi":"10.1056/nejmoa1901118","title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1932,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"LMC Diabetes & Endocrinology (Canada); Ted Rogers Centre for Heart Research","funders":"Novo Nordisk; Steno Diabetes Center Copenhagen","keywords":"Semaglutide; Type 2 diabetes; Medicine; Diabetes mellitus; Internal medicine; Cardiology; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.006867429810484486,"gpt":0.2157929557860977,"spread":0.2089255259756132,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000418249,0.000120371,0.0006619691,0.0001907121,0.000008951669,0.000004873078,0.00004292842,0.00002614304,0.00009671512],"category_scores_gemma":[0.0000811115,0.00006202322,0.00005204058,0.0001261496,0.00003459597,0.00006027096,0.00001689017,0.0001284169,0.000005392189],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000278153,"about_ca_system_score_gemma":0.00003271478,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000247611,"about_ca_topic_score_gemma":0.00000769666,"domain_scores_codex":[0.9990438,0.00003171226,0.0002384497,0.0001033764,0.0004249965,0.0001576491],"domain_scores_gemma":[0.9994558,0.00005607707,0.00008546193,0.0001558634,0.00009889534,0.0001479079],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000313644,0.00008164809,0.9253252,0.00004246775,0.0007773736,0.00004345698,0.0001271005,0.00001500332,0.00001662106,0.00001179658,0.0006341944,0.07261149],"study_design_scores_gemma":[0.07911597,0.004168463,0.8984727,0.0003607375,0.0006106264,0.000007216791,0.00004993679,0.000007847475,0.00001937777,0.00004595383,0.01707634,0.00006482471],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955382,0.001909947,0.000004322445,0.00108032,0.0002563001,0.0002354988,3.37151e-7,0.000005470599,0.0009695613],"genre_scores_gemma":[0.9982768,0.0001164885,0.0003445696,0.0003449035,0.0001979645,5.037783e-7,0.000004746511,0.0000119204,0.0007020452],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07880233,"threshold_uncertainty_score":0.2529234,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2795481136","doi":"10.1016/j.cmet.2018.03.001","title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","year":2018,"lang":"en","type":"review","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1922,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Gastric emptying; Glucagon-like peptide-1; Enteroendocrine cell; Appetite; Glycemic; Medicine; Type 2 diabetes; Glucagon-like peptide-2; Glucagon-like peptide 1 receptor; Pharmacology; Receptor; Diabetes mellitus; Endocrinology; Bioinformatics; Internal medicine; Biology; Endocrine system; Agonist; Peptide; Hormone; Biochemistry; Stomach","retraction":null,"screen_n_in":null,"score":{"opus":0.04118604965361883,"gpt":0.3156413169815026,"spread":0.2744552673278837,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001820287,0.0002497263,0.001291875,0.0002036561,0.00001985782,0.00000547584,0.00008945016,0.0001570966,0.00003388867],"category_scores_gemma":[0.00000441881,0.0001821826,0.0002563059,0.0001857774,0.00006542551,0.00002723144,0.00005422224,0.00008330726,0.00003446601],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002193064,"about_ca_system_score_gemma":0.00004666127,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001318649,"about_ca_topic_score_gemma":8.937063e-7,"domain_scores_codex":[0.9989243,0.00004828355,0.0004173934,0.0002846146,0.0001857863,0.0001396844],"domain_scores_gemma":[0.9989004,0.00003466554,0.0004999036,0.0004358673,0.00007203565,0.00005717124],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000008331085,0.000165762,0.000001177898,0.01733931,0.0004071113,4.159471e-7,0.00003319734,2.16182e-8,0.0004851978,0.00233264,0.0001472434,0.9790796],"study_design_scores_gemma":[0.0004609558,0.0001139559,0.00004293653,0.001087306,0.008207015,0.000001855431,0.00002034326,0.000006446441,0.001847058,0.0006337939,0.9874561,0.0001222007],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001248588,0.9944745,0.001333542,0.000006561738,0.000285273,0.001311638,0.00001022959,0.00002268971,0.002430751],"genre_scores_gemma":[0.0009102285,0.9952984,0.001033958,0.00003112364,0.00009391309,0.0001404062,0.00009499936,0.00003999475,0.002356996],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9873089,"threshold_uncertainty_score":0.7429193,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2775794168","doi":"10.1016/j.cjca.2017.12.005","title":"Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms","year":2017,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1838,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false},"ca_institutions":"","funders":"British Heart Foundation; Wellcome Trust","keywords":"Medicine; Diabetes mellitus; Disease; Vascular disease; Cardiology; Intensive care medicine; Internal medicine; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.0782121040416241,"gpt":0.3063625545832741,"spread":0.22815045054165,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001013511,0.0003967897,0.00457113,0.0004907394,0.0001694419,0.00006128415,0.0002101955,0.000395206,0.000005841886],"category_scores_gemma":[0.0004424675,0.0002780996,0.002008362,0.0000599616,0.0003695795,0.00007572099,0.00006860074,0.0004819819,0.000008634578],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000913862,"about_ca_system_score_gemma":0.001446866,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005625403,"about_ca_topic_score_gemma":0.00003520013,"domain_scores_codex":[0.997782,0.0003984038,0.0007603668,0.0004310288,0.0002124547,0.0004157533],"domain_scores_gemma":[0.996646,0.0001177616,0.0003639006,0.0008525127,0.0001949732,0.0018248],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000004432362,0.000003919655,0.0008495593,0.002308988,0.01564793,0.00244884,0.000004449798,0.000001366358,2.573813e-8,0.0002475896,0.004409173,0.9740737],"study_design_scores_gemma":[0.0009583001,0.0002904896,0.002755315,0.003687309,0.02844438,0.0002847805,0.000006003051,0.000001448208,2.128696e-8,0.0002707239,0.9630741,0.0002271238],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001902738,0.9972016,0.00008020006,0.0000926856,0.001087129,0.0005670483,0.00002004065,0.000006062876,0.0007549376],"genre_scores_gemma":[0.001470253,0.9968321,0.0001504531,0.0001259523,0.001179402,0.00001575041,0.00004057036,0.00005120097,0.0001342966],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9738466,"threshold_uncertainty_score":0.9999671,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3100542962","doi":"10.1056/nejmoa2030183","title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1824,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Rijksuniversiteit Groningen; Massachusetts Medical Society; Sanofi","keywords":"Heart failure; Diabetes mellitus; Medicine; Intensive care medicine; Cardiology; Internal medicine; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.009861050130002576,"gpt":0.2174310771971121,"spread":0.2075700270671095,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002402653,0.0001258159,0.0004431895,0.0001352988,0.00001690447,0.000007867301,0.00004002466,0.00003061659,0.0001048388],"category_scores_gemma":[0.0001754028,0.00007167574,0.00002190236,0.000201967,0.00004467037,0.00008296567,0.00001933327,0.000231004,0.000001990257],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000278971,"about_ca_system_score_gemma":0.00003838021,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00000366811,"about_ca_topic_score_gemma":0.000007702639,"domain_scores_codex":[0.9990265,0.00003373344,0.0002994046,0.0001145104,0.0003521145,0.0001737312],"domain_scores_gemma":[0.9993124,0.00006096951,0.0001262393,0.00006731121,0.00009198801,0.0003410712],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006904336,0.00008270687,0.8917339,0.00005280628,0.0001397253,0.00005660606,0.0007645966,0.000008067889,0.0001861693,0.0000131511,0.01461143,0.09166034],"study_design_scores_gemma":[0.1449145,0.0103391,0.6417077,0.00130686,0.0005031472,0.00001228395,0.0003575525,0.0000416424,0.0002619396,0.00006601231,0.2003427,0.0001465677],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9320747,0.0008027833,0.00002336422,0.06656773,0.00008477687,0.0001858679,4.289726e-7,0.000008408785,0.0002519774],"genre_scores_gemma":[0.9943517,0.0001142573,0.001801568,0.002824884,0.0008332396,9.212482e-7,0.000007359548,0.00001355268,0.00005254491],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2500263,"threshold_uncertainty_score":0.2922852,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2894746763","doi":"10.1016/s0140-6736(18)32261-x","title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1791,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institutes of Health; Sirtex Medical; Servier; Novo Nordisk; Boston Scientific Corporation; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Gilead Sciences; GlaxoSmithKline; Amgen; Pfizer; Daiichi Sankyo Europe; Sanofi; Abbott Laboratories","keywords":"Medicine; Placebo; Type 2 diabetes; Double blind; Disease; Internal medicine; Diabetes mellitus; Physical therapy; Alternative medicine; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.02157833320229071,"gpt":0.2493989198125698,"spread":0.2278205866102791,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009551155,0.0002949489,0.001880002,0.000108154,0.00009712986,0.00005982073,0.0001253286,0.0000482586,0.00002197638],"category_scores_gemma":[0.0001398476,0.0001511081,0.000389487,0.0001487699,0.0001687498,0.00008635391,0.00009755218,0.0001169859,0.00001346951],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002934653,"about_ca_system_score_gemma":0.00003093242,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003620638,"about_ca_topic_score_gemma":0.000009658143,"domain_scores_codex":[0.9982366,0.0001597731,0.0002750496,0.0004066484,0.0005040962,0.0004178518],"domain_scores_gemma":[0.998556,0.0001473781,0.00006118879,0.001000368,0.0000740141,0.0001610593],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5572789,0.0001768789,0.4307236,0.00004479333,0.00979421,0.00001149459,0.00009403462,0.000009170917,5.43386e-7,0.00001856828,0.0003341665,0.001513538],"study_design_scores_gemma":[0.7641599,0.0005075965,0.2290142,0.0000426626,0.004231625,1.406595e-7,0.00001795245,0.00004603002,0.000006657043,0.0000274663,0.001791699,0.0001540351],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880286,0.002862992,0.000004678441,0.0006529001,0.0002092521,0.007124015,0.000008055459,0.00005524061,0.001054301],"genre_scores_gemma":[0.9978712,0.0001934691,0.00007322595,0.0005102786,0.0002939702,0.0006188718,0.00002846133,0.00003209813,0.0003784738],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2068809,"threshold_uncertainty_score":0.616201,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2978840913","doi":"10.1016/j.molmet.2019.09.010","title":"Glucagon-like peptide 1 (GLP-1)","year":2019,"lang":"en","type":"review","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1738,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"European Research Council; BERLIN-CHEMIE; Canadian Institutes of Health Research; Merck Sharp and Dohme; Medical Research Council; Johnson and Johnson; Servier; Novo Nordisk; National Institute for Health and Care Research; Novo Nordisk Fonden; Deutsche Forschungsgemeinschaft; Zafgen; Indiana University; Banting and Best Diabetes Centre, University of Toronto; Wellcome Trust; Alexander von Humboldt-Stiftung; Novartis Pharma; Helmholtz Association; Novartis; Merck KGaA; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Merck; Pfizer; AstraZeneca; Eli Lilly and Company; Boehringer Ingelheim","keywords":"Glucagon-like peptide-1; Glucagon-like peptide-2; Glucagon; Proglucagon; Incretin; Peptide; Chemistry; Internal medicine; Diabetes mellitus; Endocrinology; Medicine; Insulin; Biochemistry; Type 2 diabetes","retraction":null,"screen_n_in":null,"score":{"opus":0.03531689130424301,"gpt":0.3185651192872342,"spread":0.2832482279829912,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001949464,0.0007449908,0.003087469,0.0004195776,0.00003927456,0.00006074815,0.000305761,0.0002512151,0.000299255],"category_scores_gemma":[0.00003491703,0.0005610141,0.001563085,0.0004119925,0.00004595266,0.00005650541,0.000242167,0.0003762696,0.003817257],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001008875,"about_ca_system_score_gemma":0.0002274015,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001292975,"about_ca_topic_score_gemma":5.126182e-7,"domain_scores_codex":[0.9974346,0.0001235113,0.0005782652,0.0007584304,0.000527146,0.0005780378],"domain_scores_gemma":[0.9980612,0.00003313414,0.0002696078,0.001341488,0.00006353128,0.000231051],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000005299974,0.0001730814,0.000001033908,0.01375623,0.002284678,0.0003935673,0.00001134183,2.443838e-7,0.000007834992,0.002599201,0.006460624,0.9743069],"study_design_scores_gemma":[0.000823611,0.00005012619,0.00001109628,0.004216126,0.01986102,0.00002637216,0.000003277259,0.000001350739,0.00001868375,0.00003180304,0.9745051,0.0004514474],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001136368,0.9565641,0.00008625213,0.00004785788,0.001253841,0.002321816,0.00002312891,0.0001395152,0.03955213],"genre_scores_gemma":[0.000003199545,0.9466925,0.0009644515,0.000826755,0.000252119,0.0002897599,0.00065991,0.0001832246,0.05012809],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9738554,"threshold_uncertainty_score":0.9996842,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2083342497","doi":"10.1001/jama.290.4.486","title":"Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance","year":2003,"lang":"en","type":"article","venue":"JAMA","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1623,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Hôtel-Dieu de Montréal; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Bayer","keywords":"Medicine; Acarbose; Impaired glucose tolerance; Internal medicine; Hazard ratio; Postprandial; Placebo; Heart failure; Diabetes mellitus; Body mass index; Randomized controlled trial; Surgery; Type 2 diabetes; Endocrinology; Insulin; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.006003306144631211,"gpt":0.1812743189844947,"spread":0.1752710128398635,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001168723,0.00009913013,0.0002651419,0.00003425444,0.0000251746,0.00000806647,0.00001418515,0.00001798739,0.000002104197],"category_scores_gemma":[0.0000441969,0.00004808431,0.00006319231,0.000065834,0.00007171786,0.00004057598,0.0000126152,0.00002885828,5.87338e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002711779,"about_ca_system_score_gemma":0.00001165978,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001215738,"about_ca_topic_score_gemma":0.000004787423,"domain_scores_codex":[0.9994557,0.00006986001,0.00009157436,0.0001558899,0.0001260805,0.0001009123],"domain_scores_gemma":[0.9995839,0.00003331198,0.00003217663,0.0002540141,0.00002881777,0.00006779969],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001698758,0.0005071969,0.913453,0.0000435241,0.001131797,0.00002816777,0.0002175582,0.00005962489,0.000003568756,0.00009325544,0.00002130343,0.08274227],"study_design_scores_gemma":[0.03346744,0.0004696376,0.9627662,0.00007145405,0.001439614,5.553779e-7,0.00004059893,0.0002186825,0.0001131207,0.00004744868,0.001310085,0.00005521224],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991979,0.006857526,0.000002665587,0.0001169193,0.00001540437,0.0007684614,0.000005296502,0.000007396884,0.0002473354],"genre_scores_gemma":[0.9979072,0.001808475,0.00009343082,0.00006822906,0.000008634595,0.00004170606,0.000007390461,0.000007783347,0.00005712974],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08268707,"threshold_uncertainty_score":0.1960821,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3195404919","doi":"10.1016/s2213-8587(21)00203-5","title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","year":2021,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1502,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"British Heart Foundation","keywords":"Medicine; Type 2 diabetes; Meta-analysis; Glucagon-like peptide 1 receptor; Diabetes mellitus; MEDLINE; Internal medicine; Intensive care medicine; Bioinformatics; Pharmacology; Receptor; Endocrinology; Agonist","retraction":null,"screen_n_in":null,"score":{"opus":0.1140068583100207,"gpt":0.354532624794316,"spread":0.2405257664842952,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.002703065,0.0007991219,0.03427921,0.00044068,0.00004577395,0.00004184892,0.0002946333,0.0001307259,0.0001146752],"category_scores_gemma":[0.00132475,0.0003454382,0.00240199,0.001101073,0.0002592816,0.0000547156,0.0002198219,0.0002998257,0.000003688514],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007271462,"about_ca_system_score_gemma":0.0001210463,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000238064,"about_ca_topic_score_gemma":0.00001753774,"domain_scores_codex":[0.9936857,0.002540497,0.001660836,0.0007564456,0.0004932742,0.000863297],"domain_scores_gemma":[0.9952771,0.00145259,0.001166804,0.001752674,0.0001981283,0.0001527214],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.00004237175,0.0001319984,0.01730679,0.3527782,0.6279024,0.0000121526,0.00001768603,3.667163e-7,2.914291e-8,0.00003438869,0.0001808596,0.001592741],"study_design_scores_gemma":[0.008046284,0.0003256675,0.001360664,0.02436918,0.9491814,0.000001116051,0.000006327069,5.974013e-7,8.802857e-7,0.000002624033,0.01638549,0.0003197505],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00275079,0.987542,5.798544e-7,0.0003191404,0.00005344176,0.009013883,0.0002085351,0.00003324956,0.00007833735],"genre_scores_gemma":[0.0003782268,0.9948336,0.0001287122,0.001124774,0.00002264421,0.002389544,0.0008762476,0.00006072186,0.0001855537],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.328409,"threshold_uncertainty_score":0.9998997,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1967442749","doi":"10.1016/j.cmet.2013.04.008","title":"Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action","year":2013,"lang":"en","type":"review","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1459,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Incretin; Hormone; Receptor; Glucagon-like peptide-1; Biology; Type 2 diabetes; Bioinformatics; Endocrinology; Medicine; Internal medicine; Diabetes mellitus","retraction":null,"screen_n_in":null,"score":{"opus":0.0396611549816419,"gpt":0.3237420682007974,"spread":0.2840809132191555,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001538077,0.0003618282,0.001934278,0.0002373053,0.00003057963,0.000007919134,0.0001007579,0.0002614497,0.0003558124],"category_scores_gemma":[0.000007815051,0.0002569979,0.0002795955,0.0001486692,0.00009463073,0.0000522802,0.0001493842,0.0002288194,0.0001580457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002746187,"about_ca_system_score_gemma":0.00004642949,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000016518,"about_ca_topic_score_gemma":1.085307e-7,"domain_scores_codex":[0.9987555,0.0001206388,0.0003928013,0.0003613439,0.0001207651,0.000248988],"domain_scores_gemma":[0.9991446,0.00006078653,0.0003716352,0.0002617745,0.00004737961,0.0001138643],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000165633,0.0002401117,1.676525e-7,0.01714819,0.0009152694,0.000006668859,0.00001583982,2.447103e-8,0.01535947,0.0009958615,0.008602692,0.9566991],"study_design_scores_gemma":[0.001010226,0.0001301868,0.00003403977,0.000450193,0.01069892,0.000005371914,0.00001419402,0.000002361823,0.003162597,0.0003225192,0.9839874,0.0001819919],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005413822,0.994997,0.0000338106,0.00002207624,0.0005672114,0.001698274,0.00001595453,0.000044311,0.002079928],"genre_scores_gemma":[0.0001963179,0.9943817,0.001001131,0.00009262819,0.0002529248,0.0003194934,0.0001769327,0.00004683458,0.00353201],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9753847,"threshold_uncertainty_score":0.9999882,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2111824270","doi":"10.1016/s0140-6736(10)60576-4","title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","year":2010,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1422,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St Joseph's Health Care","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Diabetes mellitus; Randomized controlled trial; Internal medicine; Type 2 diabetes; Creatinine; Renal function; Diabetic retinopathy; Dialysis; Renal replacement therapy; Kidney disease; Surgery; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.01705988179708621,"gpt":0.2958858045236296,"spread":0.2788259227265434,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004399727,0.0001310337,0.001255346,0.0001326004,0.00001308993,0.000003156309,0.0001682896,0.00004287947,0.00003480936],"category_scores_gemma":[0.0003233424,0.00005388175,0.0004104981,0.0003489007,0.0000894613,0.00001579105,0.00002603095,0.00006784109,0.000001754751],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002760636,"about_ca_system_score_gemma":0.0000160826,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009246324,"about_ca_topic_score_gemma":0.00009863667,"domain_scores_codex":[0.9991379,0.0001685069,0.0002605552,0.0001288366,0.0001648204,0.0001394188],"domain_scores_gemma":[0.9984823,0.0004093653,0.0001656792,0.0008379802,0.00008267635,0.00002201828],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1542957,0.001495199,0.7617761,0.0001519065,0.01288574,0.000005488075,0.001015358,0.000103206,0.04618161,0.0001117077,0.0002446338,0.02173336],"study_design_scores_gemma":[0.3728263,0.009932801,0.3584057,0.00008701251,0.01339131,1.671701e-7,0.0001320118,0.0003504331,0.244289,0.00002547695,0.00044809,0.0001116705],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976554,0.00008496142,2.134517e-7,0.0004114575,0.0002273204,0.001301817,0.00001012075,0.000007295271,0.0003014117],"genre_scores_gemma":[0.9994853,0.00005620817,0.00002197066,0.0001602855,0.00006779191,0.00004739185,0.00002248539,0.000008368548,0.0001302492],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4033704,"threshold_uncertainty_score":0.2197234,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2492672367","doi":"10.1161/circulationaha.116.021887","title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","year":2016,"lang":"en","type":"review","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1346,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Diabetes Canada; University of Toronto; Toronto General Hospital; St. Michael's Hospital; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Empagliflozin; Medicine; Internal medicine; Renal function; Diabetes mellitus; Tubuloglomerular feedback; Endocrinology; Kidney disease; Canagliflozin; Dapagliflozin; Cardiology; Blood pressure; Heart failure; Myocardial infarction; Type 2 diabetes; Urology","retraction":null,"screen_n_in":null,"score":{"opus":0.0317982732403083,"gpt":0.2908156015844842,"spread":0.2590173283441759,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001354895,0.0002740983,0.0009665041,0.0002230249,0.00001996473,0.00001014979,0.00007066855,0.0001396966,0.00005221814],"category_scores_gemma":[0.000005270803,0.0001363499,0.0004459475,0.0002098717,0.0000435913,0.0000470042,0.000004570692,0.00004703851,0.00006081834],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002489558,"about_ca_system_score_gemma":0.00005288931,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000005974595,"about_ca_topic_score_gemma":0.000003898404,"domain_scores_codex":[0.9987403,0.00007393146,0.0005070755,0.0002545379,0.000220516,0.000203672],"domain_scores_gemma":[0.9992039,0.0001044826,0.0002216827,0.0004083991,0.00002545644,0.00003609278],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000003084892,0.000483047,0.003805905,0.00355147,0.0003005822,0.000009247933,0.0001772703,2.164109e-7,0.000002729866,0.0001248315,0.00005984819,0.9914818],"study_design_scores_gemma":[0.0009948628,0.0002058195,0.005860493,0.006981282,0.002518954,7.310051e-7,0.00001044917,0.000002640573,0.00002499322,0.00006632054,0.9831973,0.0001362067],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003898978,0.9924999,0.000006339162,0.00006711505,0.0001769102,0.002096021,0.00001721013,0.00002063149,0.001216924],"genre_scores_gemma":[0.01951678,0.9793608,0.0000139801,0.00002183629,0.0001798537,0.0002973369,0.0004795907,0.00002736898,0.0001024694],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9913456,"threshold_uncertainty_score":0.5560189,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1990025047","doi":"10.1161/circulationaha.113.005081","title":"Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus","year":2013,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1307,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"American Diabetes Association","keywords":"Empagliflozin; Medicine; Renal function; Glomerular hyperfiltration; Internal medicine; Effective renal plasma flow; Endocrinology; Renal blood flow; Diabetes mellitus; Tubuloglomerular feedback; Plasma renin activity; Aldosterone; Filtration fraction; Type 2 diabetes; Urology; Renin–angiotensin system; Blood pressure; Diabetic nephropathy","retraction":null,"screen_n_in":null,"score":{"opus":0.003918426627373016,"gpt":0.1937316932782741,"spread":0.1898132666509011,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006224938,0.00009367136,0.0001792605,0.0001155972,0.00001186782,0.000006484671,0.00001222621,0.00003992784,0.00008399776],"category_scores_gemma":[0.000006163818,0.00006949144,0.00003030804,0.0001572438,0.0000229718,0.0001388746,0.000004515643,0.0000389027,0.00003416465],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006497666,"about_ca_system_score_gemma":0.000007424307,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001771825,"about_ca_topic_score_gemma":0.000004474472,"domain_scores_codex":[0.9994032,0.00002142625,0.0001561884,0.0001330672,0.0001614683,0.0001246383],"domain_scores_gemma":[0.9996947,0.00001730946,0.00006167032,0.0001258584,0.00006754654,0.0000328836],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001033685,0.0001677175,0.9832967,0.0001432331,0.00005525663,0.00000135056,0.00004495159,0.00007447142,0.004699416,0.00001920793,0.00002215199,0.01137216],"study_design_scores_gemma":[0.003519818,0.000547872,0.9857152,0.0001646331,0.0001404473,6.63803e-8,0.000002139235,0.001155147,0.008612393,0.00006351636,0.00001256786,0.00006627354],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.998355,0.00007561956,0.00004535656,0.00002727399,0.00003825168,0.0009643092,0.000001476022,0.00002197132,0.0004707693],"genre_scores_gemma":[0.9992701,0.000004684986,0.00006733922,0.00003031343,0.00001202646,0.00003832453,0.000549597,0.00001172842,0.00001583263],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01130589,"threshold_uncertainty_score":0.2833779,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3133746780","doi":"10.1016/s0140-6736(21)00213-0","title":"Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1302,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Placebo; Overweight; Type 2 diabetes; Internal medicine; Body mass index; Diabetes mellitus; Randomized controlled trial; Glycated hemoglobin; Physical therapy; Endocrinology; Liraglutide","retraction":null,"screen_n_in":null,"score":{"opus":0.03487184394042082,"gpt":0.2963627505833139,"spread":0.2614909066428931,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006209242,0.0002971999,0.001262304,0.00009934528,0.00009370006,0.00009883427,0.0001620827,0.00007468906,0.0002068324],"category_scores_gemma":[0.00009203162,0.0001580177,0.000100254,0.0004017768,0.00009523099,0.0001014276,0.0001266972,0.0002266259,0.00003348245],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007071379,"about_ca_system_score_gemma":0.0001533594,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005995534,"about_ca_topic_score_gemma":0.0006478812,"domain_scores_codex":[0.998228,0.0001268694,0.0003644863,0.0004219822,0.0003317782,0.0005268863],"domain_scores_gemma":[0.9986269,0.000430324,0.0001450597,0.0005831245,0.00008583054,0.0001287301],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9875396,0.001312711,0.003656688,0.0002466573,0.0007060678,0.0003438985,0.0003826443,0.000008822999,0.00008323399,0.0003350973,0.003389992,0.001994524],"study_design_scores_gemma":[0.9877294,0.002182727,0.0003395476,0.0006263237,0.0007962508,0.00001198666,0.0001972789,0.0006027428,0.0007168607,0.00004617873,0.006536796,0.0002139333],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817209,0.001884005,0.000008457387,0.00329833,0.0002112044,0.004823789,0.0000110675,0.00007631468,0.007965976],"genre_scores_gemma":[0.9894935,0.000672371,0.0005195332,0.001012759,0.0008645568,0.0007468836,0.00008217701,0.0000407621,0.006567459],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007772643,"threshold_uncertainty_score":0.6443776,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3092379111","doi":"10.1001/jamacardio.2020.4511","title":"Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes","year":2020,"lang":"en","type":"review","venue":"JAMA Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1212,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; University of Toronto","funders":"Vetenskapsrådet; Novo Nordisk; Sanofi; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Type 2 diabetes; Hazard ratio; Internal medicine; Kidney disease; Population; Diabetes mellitus; Stroke (engine); Meta-analysis; Randomized controlled trial; Myocardial infarction; Intensive care medicine; Confidence interval; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.00868940045644245,"gpt":0.2293920422134082,"spread":0.2207026417569657,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002384922,0.0003206805,0.003434353,0.0001986405,0.00001375477,0.00000956325,0.00006121354,0.0002799224,0.0000044609],"category_scores_gemma":[0.0002306025,0.0001931767,0.000366454,0.0002954814,0.00005053395,0.00004667971,0.00007458692,0.0002299689,0.000006812056],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002207644,"about_ca_system_score_gemma":0.0001255457,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000009760762,"about_ca_topic_score_gemma":0.000001613338,"domain_scores_codex":[0.9985165,0.0001960723,0.0003410567,0.0003820502,0.0003074497,0.0002568481],"domain_scores_gemma":[0.9990998,0.0001088769,0.0002524808,0.0003149574,0.0001123299,0.0001115831],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003188201,0.00004215882,0.7097538,0.004353718,0.0136717,0.00003286147,0.00001733258,0.000001125016,1.950131e-8,0.000005040324,0.001203521,0.2708868],"study_design_scores_gemma":[0.002926975,0.001109928,0.08056299,0.00252892,0.01005545,0.000001091633,0.000005770892,3.081203e-7,3.730472e-7,0.000001381428,0.902619,0.0001877924],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01119996,0.9856142,0.000001455053,0.0001544442,0.0001911016,0.0016649,0.00005376448,0.00003097504,0.001089202],"genre_scores_gemma":[0.002840097,0.9957287,0.0001358126,0.0001378143,0.0001430971,0.000114717,0.0006268952,0.00005561306,0.0002172933],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9014155,"threshold_uncertainty_score":0.7877519,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2153449155","doi":"10.2337/dc06-9912","title":"Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy","year":2006,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1212,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; MEDLINE; Algorithm; Internal medicine; Intensive care medicine; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.01288775741693486,"gpt":0.2470048069992704,"spread":0.2341170495823355,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009552354,0.000129026,0.0002712911,0.00009751476,0.00002192744,0.000004963039,0.00005265743,0.00004190992,0.00001004924],"category_scores_gemma":[0.000005737576,0.0000909248,0.00006652655,0.0001775859,0.00007045778,0.00002120531,0.00003263821,0.00003475329,0.000001586015],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004654006,"about_ca_system_score_gemma":0.00001371781,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001199486,"about_ca_topic_score_gemma":0.000004887599,"domain_scores_codex":[0.9992152,0.00001722516,0.000253274,0.0001660081,0.0001484755,0.0001998581],"domain_scores_gemma":[0.9994334,0.0001255262,0.0001002974,0.0002021752,0.0001160755,0.00002254461],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.00007299653,0.000275194,0.2507315,0.0007787924,0.000461122,0.000003119848,0.0003005581,0.00003305158,0.0007589779,0.000614211,0.0006188847,0.7453516],"study_design_scores_gemma":[0.008630288,0.001499165,0.9570247,0.0005295678,0.0006527501,1.383998e-7,0.002503157,0.002292477,0.02117766,0.00037345,0.005117398,0.0001992595],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9770662,0.02022428,0.00001227047,0.0001488548,0.0001214586,0.001446204,0.00005063666,0.0000159951,0.0009140722],"genre_scores_gemma":[0.9960074,0.0009922371,0.002363389,0.0001316402,0.00004026975,0.0001998425,0.0001621715,0.00001746817,0.00008552192],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7451524,"threshold_uncertainty_score":0.3707806,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3101044784","doi":"10.1056/nejmoa2030186","title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1174,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; Women's College Hospital; University of Toronto; St. Michael's Hospital","funders":"Sanofi","keywords":"Diabetes mellitus; Medicine; Kidney disease; Disease; Intensive care medicine; Internal medicine; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.007553549224811723,"gpt":0.2149278698987701,"spread":0.2073743206739584,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001505739,0.0001224042,0.0003671508,0.0001169793,0.00001396723,0.000006256401,0.00004821897,0.0000196779,0.00011689],"category_scores_gemma":[0.0002443243,0.00006846493,0.00002493497,0.0001377917,0.00005821864,0.00008338207,0.0000193693,0.0001636044,0.000002342203],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004589303,"about_ca_system_score_gemma":0.0001302073,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002792762,"about_ca_topic_score_gemma":0.000002283099,"domain_scores_codex":[0.9991087,0.00002576267,0.000258921,0.0001115251,0.0003321046,0.0001630235],"domain_scores_gemma":[0.9988165,0.00004023442,0.000120574,0.00007691896,0.00006074369,0.0008849845],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00122185,0.0001215205,0.911196,0.000162824,0.0001650597,0.0001595593,0.0003592353,0.000006648607,0.00008271148,0.00003058051,0.010521,0.07597303],"study_design_scores_gemma":[0.1658641,0.009029322,0.7780489,0.001294718,0.0007373071,0.000002429665,0.00004165258,0.0001104597,0.000062197,0.00009294297,0.04460552,0.0001105199],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9614594,0.001767335,0.00002685112,0.03609717,0.0000962741,0.0002168882,0.000001913403,0.000008166619,0.0003259811],"genre_scores_gemma":[0.9949267,0.0001449665,0.0001643502,0.003437237,0.001192299,0.000001241833,0.00001632128,0.00001276311,0.0001041047],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1646422,"threshold_uncertainty_score":0.2791919,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2138077952","doi":"10.1016/s0140-6736(08)61206-4","title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","year":2008,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1068,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"Novo Nordisk; Amylin Pharmaceuticals; Eli Lilly and Company","keywords":"Exenatide; Medicine; Type 2 diabetes; Open label; Internal medicine; Diabetes mellitus; Randomized controlled trial; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.1022408823819575,"gpt":0.3476723919092116,"spread":0.2454315095272541,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003685594,0.0001873654,0.0006975404,0.00002795084,0.0002078891,0.0000287326,0.0004056486,0.00002596092,0.00003113341],"category_scores_gemma":[0.00008505661,0.00009098395,0.00007471968,0.000180159,0.00009815815,0.00006848579,0.00008660772,0.00005616659,0.00002677122],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000093745,"about_ca_system_score_gemma":0.00006037453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000147767,"about_ca_topic_score_gemma":0.00005377131,"domain_scores_codex":[0.9989735,0.00005961107,0.0002335566,0.0002208354,0.0002047963,0.0003076248],"domain_scores_gemma":[0.9982052,0.0007032724,0.0001186637,0.000837224,0.00008590398,0.00004968961],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3033689,0.04241494,0.2788356,0.0005760752,0.02465954,0.0001817832,0.03280749,0.0001346865,0.003859934,0.001246628,0.1757042,0.1362102],"study_design_scores_gemma":[0.6417811,0.03995301,0.1074707,0.0001452687,0.004753331,0.000001777779,0.002080066,0.0015482,0.002160736,0.0001056316,0.199589,0.0004111789],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845809,0.0009754177,0.000019953,0.002308665,0.0003895037,0.005850304,0.00002023662,0.00003642641,0.005818558],"genre_scores_gemma":[0.9932675,0.001207175,0.0004781076,0.0003697975,0.0003959283,0.0008405547,0.0000220098,0.00002282782,0.003396086],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3384122,"threshold_uncertainty_score":0.3710218,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2000976083","doi":"10.1161/circulationaha.107.739938","title":"Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways","year":2008,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1046,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Medicine; Glucagon-like peptide-1; Internal medicine; Glucagon-like peptide 1 receptor; Vasodilation; Endocrinology; Nitric oxide; Agonist; Receptor; Dipeptidyl peptidase-4; Pharmacology; Nitric oxide synthase; Incretin; Type 2 diabetes; Diabetes mellitus","retraction":null,"screen_n_in":null,"score":{"opus":0.03600998559058563,"gpt":0.2445760992201535,"spread":0.2085661136295679,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002539861,0.000357424,0.0006076685,0.0002147468,0.0002925964,0.00002688529,0.00007627394,0.0002152542,0.0001193288],"category_scores_gemma":[0.00007422538,0.0003452209,0.0001571802,0.000270945,0.0002028026,0.0003279495,0.00009967302,0.0002455969,0.00005141347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003699167,"about_ca_system_score_gemma":0.0001035223,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002087332,"about_ca_topic_score_gemma":0.0000438582,"domain_scores_codex":[0.9977943,0.00008448255,0.0004834779,0.000653162,0.0006142151,0.0003703793],"domain_scores_gemma":[0.9986903,0.00008342262,0.0003621976,0.0004580013,0.0002011636,0.0002049143],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007358707,0.001460954,0.822354,0.001028762,0.003398254,0.0001330505,0.01167309,0.0004015724,0.1389813,0.0008914837,0.006690837,0.01225083],"study_design_scores_gemma":[0.00433326,0.0003368238,0.9724794,0.0003265156,0.0006415369,0.00005772688,0.00235546,0.0002443789,0.006439121,0.0001692122,0.01214539,0.0004711468],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921642,0.001369389,0.0004721364,0.000184593,0.0005408939,0.001563082,0.00006369763,0.0001357902,0.003506236],"genre_scores_gemma":[0.9965622,0.001325656,0.0006709409,0.0001488025,0.0001694259,0.0001739291,0.0002381082,0.00005639098,0.000654575],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1501254,"threshold_uncertainty_score":0.9999,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2125468958","doi":"10.1056/nejmoa1006524","title":"Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1042,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Diabetes mellitus; Intensive care medicine; Type 2 diabetes; Disease; Intensive care; Term (time); Internal medicine; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.02154063803259014,"gpt":0.2550016657156834,"spread":0.2334610276830933,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004199103,0.0001703336,0.0009097465,0.0002679602,0.00001522578,0.000002215098,0.00009796264,0.00004106446,0.00009408151],"category_scores_gemma":[0.0006193951,0.00009661352,0.0003016763,0.00009831024,0.00006940272,0.00005459044,0.00002670157,0.0001802331,0.000006611843],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004444438,"about_ca_system_score_gemma":0.00003443355,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004793394,"about_ca_topic_score_gemma":0.000003425858,"domain_scores_codex":[0.9987423,0.00003611531,0.0004065818,0.000113849,0.0005286486,0.0001724642],"domain_scores_gemma":[0.9987891,0.0001489288,0.0002273017,0.0002793884,0.0003231417,0.0002321165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.001842375,0.0004941595,0.2380251,0.0007041979,0.008154726,0.00609564,0.00334338,0.000007167918,0.002201698,0.0001266789,0.002883586,0.7361212],"study_design_scores_gemma":[0.1179531,0.01396064,0.8116277,0.004524079,0.005967012,0.000388314,0.0002251492,0.000002372378,0.04014126,0.0001859308,0.004839809,0.000184665],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882347,0.005701921,0.0005257842,0.0007987271,0.001193502,0.0002739182,2.600445e-7,0.00001200072,0.003259184],"genre_scores_gemma":[0.9966704,0.000927559,0.0001933176,0.0007367518,0.0008762258,0.000001461684,0.000002164014,0.00001771824,0.0005743696],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7359366,"threshold_uncertainty_score":0.3939785,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2884466498","doi":"10.1007/s00125-018-4670-7","title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","year":2018,"lang":"en","type":"review","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":964,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"University of Glasgow; Novo Nordisk; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Empagliflozin; Natriuresis; Afterload; Heart failure; Medicine; Adipokine; Context (archaeology); Diuresis; Diabetes mellitus; Pharmacology; Type 2 diabetes; Internal medicine; Endocrinology; Kidney; Blood pressure; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.02485564613699635,"gpt":0.2764991405902196,"spread":0.2516434944532232,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005874218,0.0004132504,0.003573215,0.0001415772,0.00003165165,0.000006297507,0.0002235347,0.0001427635,0.00004040248],"category_scores_gemma":[0.0001210356,0.0002418404,0.001481949,0.0004082693,0.0001955183,0.00003190684,0.0003033875,0.0001654503,0.00003897738],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005623659,"about_ca_system_score_gemma":0.00008323258,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000005830083,"about_ca_topic_score_gemma":0.000001105971,"domain_scores_codex":[0.997982,0.0001184828,0.0007774726,0.0004357165,0.0003933015,0.0002929961],"domain_scores_gemma":[0.9981765,0.00007323136,0.0005088582,0.001035323,0.0001204292,0.00008572375],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000001979804,0.00008690266,0.00004602193,0.1377697,0.003834778,0.000009149229,0.000006638267,5.897972e-8,3.817514e-7,0.0003915074,0.005228553,0.8526243],"study_design_scores_gemma":[0.0002878722,0.0002654346,0.00003216489,0.08480082,0.01562412,0.000006449106,0.000001738405,3.409938e-7,0.00008685765,0.0004032944,0.8983076,0.0001832663],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00006692722,0.9958741,0.0000294489,0.00003920481,0.000332607,0.0025128,0.00004816279,0.00002893574,0.001067832],"genre_scores_gemma":[0.00003998505,0.9982575,0.0003502986,0.0001367494,0.00003795918,0.0001885216,0.00009007037,0.00004351732,0.0008554196],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8930791,"threshold_uncertainty_score":0.9861963,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4224218205","doi":"10.1111/dom.14725","title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":921,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"McMaster University; York University","funders":"Novo Nordisk; National Institute for Health and Care Research","keywords":"Semaglutide; Medicine; Placebo; Weight loss; Body mass index; Randomized controlled trial; Internal medicine; Physical therapy; Diabetes mellitus; Obesity; Type 2 diabetes; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.005126095142822623,"gpt":0.2057054038277823,"spread":0.2005793086849597,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007927474,0.0002783969,0.0008365853,0.0002442577,0.0002875505,0.00003668484,0.0001141215,0.00006303848,0.00001991786],"category_scores_gemma":[0.0001616047,0.0001907309,0.0001930273,0.0004024648,0.0002006995,0.00009137145,0.0004241711,0.0002382965,0.000004124277],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001972313,"about_ca_system_score_gemma":0.00003234351,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003137277,"about_ca_topic_score_gemma":0.000002708498,"domain_scores_codex":[0.9980699,0.0003021571,0.0002883507,0.0004299586,0.0004817069,0.0004279576],"domain_scores_gemma":[0.998845,0.000317493,0.0001406393,0.0004705282,0.00005899658,0.0001672778],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004747176,0.004453789,0.6668625,0.003372001,0.008098166,0.0004126835,0.006508928,0.00002079038,0.02216901,0.01554211,0.02607604,0.2417368],"study_design_scores_gemma":[0.02856112,0.0006605579,0.766233,0.00006904605,0.003147943,0.000007686556,0.000227449,0.0001419313,0.004798244,0.0005110516,0.1955077,0.0001343193],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.962288,0.03465844,0.000007355785,0.0002278925,0.0006223837,0.001472712,0.00002806173,0.00004789494,0.0006472416],"genre_scores_gemma":[0.9959238,0.0007230308,0.0002511468,0.0008502105,0.0002755601,0.0003998313,0.00002786609,0.00002941214,0.001519142],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2416024,"threshold_uncertainty_score":0.7777783,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2273304042","doi":"10.1093/eurheartj/ehv728","title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME <sup>®</sup> trial","year":2016,"lang":"en","type":"erratum","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":902,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Empagliflozin; Medicine; Heart failure; Hazard ratio; Internal medicine; Discontinuation; Cardiology; Diabetes mellitus; Type 2 diabetes; Placebo; Adverse effect; Confidence interval; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.01483249620450412,"gpt":0.2332985587299601,"spread":0.218466062525456,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001719485,0.0007604962,0.002004336,0.0004341566,0.0002557358,0.00008358275,0.000438357,0.0001881579,0.0001194527],"category_scores_gemma":[0.0004213623,0.0003521164,0.0009439748,0.0004280782,0.0002124347,0.0001654474,0.0003276354,0.001492759,0.0001602282],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003870255,"about_ca_system_score_gemma":0.0002229956,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000290331,"about_ca_topic_score_gemma":0.00003337163,"domain_scores_codex":[0.994357,0.001231289,0.001124981,0.0006759251,0.001800308,0.0008104439],"domain_scores_gemma":[0.9969053,0.0001413922,0.0007477216,0.001527779,0.0003581554,0.0003196585],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00559575,0.0003015815,0.5940022,0.0000790123,0.002572401,0.00006710199,0.0001078329,0.00008162169,3.869136e-7,6.00766e-7,0.3968639,0.0003275479],"study_design_scores_gemma":[0.05521041,0.002674208,0.5440894,0.001197101,0.001474801,0.000007751943,0.00002415988,0.000001455971,0.00000657284,0.000001674212,0.3950185,0.0002939813],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9867085,0.0009450814,0.000001007751,0.001869137,0.003839527,0.002063784,0.0001705093,0.00005496847,0.004347545],"genre_scores_gemma":[0.8492145,0.0002978261,0.0006965348,0.0008254217,0.003636554,0.00002763119,0.000399594,0.0005116517,0.1443903],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1400428,"threshold_uncertainty_score":0.9998931,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4214940159","doi":"10.1038/s41591-021-01659-1","title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":895,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Manitoba","funders":"Duke Clinical Research Institute; Max Rady College of Medicine, University of Manitoba; Akershus Universitetssykehus; Sahlgrenska Universitetssjukhuset; Capital Medical University; Rijksuniversiteit Groningen; Institut National de la Santé et de la Recherche Médicale; Göteborgs Universitet; Boehringer Ingelheim; National University of Singapore; School of Medicine, University of Missouri; Universität Heidelberg; Masarykova Univerzita; Universidade do Porto; Uniwersytet Łódzki; Vanderbilt University Medical Center; KU Leuven; University of Missouri; University of Missouri-Kansas City; Saint Luke's Health System; Université de Lorraine; Vanderbilt University; Universitair Medisch Centrum Groningen; Eli Lilly and Company; National University Health System; University of New South Wales; U.S. Department of Veterans Affairs","keywords":"Empagliflozin; Medicine; Heart failure; Ejection fraction; Clinical endpoint; Placebo; Internal medicine; Randomized controlled trial; Acute decompensated heart failure; Cardiology; Hazard ratio; Confidence interval; Randomization; Clinical trial; Diabetes mellitus; Type 2 diabetes; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.004595019715807455,"gpt":0.2794361358209175,"spread":0.2748411161051101,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001486929,0.0002139293,0.0007676904,0.0002262159,0.000259166,0.00001377281,0.0001477451,0.0001034909,0.0001784686],"category_scores_gemma":[0.001566664,0.0001228122,0.0002302139,0.0003688635,0.0001385908,0.00005014033,0.0001032443,0.0005109491,0.000003882987],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002298508,"about_ca_system_score_gemma":0.00006420429,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000107365,"about_ca_topic_score_gemma":0.000007118441,"domain_scores_codex":[0.9977794,0.000181453,0.000508784,0.0003198711,0.0008803695,0.0003301235],"domain_scores_gemma":[0.9985172,0.0008175242,0.0001593439,0.0002617558,0.0001528317,0.00009138069],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7700093,0.0009563514,0.002974078,0.00003094432,0.0008359515,0.0000110598,0.0003611087,0.000002393956,0.00005495887,0.002005163,0.2202997,0.002458925],"study_design_scores_gemma":[0.817117,0.002376083,0.003634175,0.00004336602,0.0006163464,9.767192e-7,0.00009524805,0.0001537225,0.00005212921,0.0003707595,0.175435,0.000105226],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9102087,0.001106958,0.00002615763,0.07221526,0.003925583,0.01168925,0.00004856048,0.00008122051,0.0006982881],"genre_scores_gemma":[0.9874256,0.00002891391,0.0007894816,0.003346127,0.0008254374,0.003606426,0.0008845327,0.0000354718,0.003058065],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07721683,"threshold_uncertainty_score":0.5008136,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3036816724","doi":"10.1016/j.jacbts.2020.02.004","title":"Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors","year":2020,"lang":"en","type":"review","venue":"JACC Basic to Translational Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":872,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; St. Michael's Hospital; University of Alberta","funders":"Boehringer Ingelheim; Novo Nordisk; Sanofi; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Servier; Amgen","keywords":"Medicine; Empagliflozin; Heart failure; Natriuresis; Internal medicine; Diabetes mellitus; Endocrinology; Cardiology; Oxidative stress; Pharmacology; Blood pressure; Type 2 diabetes","retraction":null,"screen_n_in":null,"score":{"opus":0.0328152155289663,"gpt":0.2903976320520634,"spread":0.2575824165230971,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005943,0.0003425702,0.001665091,0.0004458615,0.00006082031,0.00001495733,0.0003650122,0.0001169651,0.0001216615],"category_scores_gemma":[0.00002245596,0.0002687657,0.001082146,0.001363006,0.0002122409,0.0001489713,0.00003177857,0.0001393959,0.00004431666],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007713564,"about_ca_system_score_gemma":0.0006023264,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002091021,"about_ca_topic_score_gemma":0.000002777466,"domain_scores_codex":[0.9966831,0.00003091676,0.00074879,0.0006469221,0.00157354,0.0003167569],"domain_scores_gemma":[0.9988558,0.000058788,0.0002053808,0.0004513044,0.0001613604,0.0002673869],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000193519,0.000152664,0.00001994706,0.005198226,0.0007275229,0.00001196774,0.000144309,0.0000550205,0.00007610373,0.004381254,0.00006751045,0.9891461],"study_design_scores_gemma":[0.0007934461,0.0003544191,0.0007928287,0.005409719,0.004586594,0.000006015513,0.00001186035,0.00001275454,0.002120071,0.0001832295,0.9854061,0.0003229667],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002249014,0.9923477,0.001859922,0.0002948706,0.0002593868,0.002113667,0.0002474153,0.00003895759,0.002613136],"genre_scores_gemma":[0.01106691,0.9820077,0.006040917,0.0001356643,0.000163577,0.0001392249,0.0002647591,0.00005569145,0.0001255499],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9888232,"threshold_uncertainty_score":0.9999765,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}